ADMINISTRATIVE CURRICULUM VITAE
Jeffrey N. Bryan, DVM, MS, PhD, DACVIM(Oncology)

Present Positions and Addresses: Professor of Oncology
Section Head, Oncology
Associate Department Chair for Research and Graduate Studies and Multispecies Sections
Associate Director of Comparative Oncology and Translational Medicine, Ellis Fischel Cancer Center
Director of the Scott Endowed Program in Veterinary Oncology
Director of the PET Imaging Center

Office address: Department of Veterinary Medicine and Surgery
College of Veterinary Medicine
A 304 Clydesdale Hall
900 East Campus Drive
Columbia, MO 65211

ORCID ID: 0000-0002-6820-9850

Education:

Institution and Location	Degree	Year	Field of Study
University of California - Davis Davis, CA	BS	1991	Veterinary Sciences
University of California - Davis Davis, CA	DVM	1993	Veterinary Medicine G.P.A.: 3.7 Class Rank: 13/122
University of Missouri-Columbia Columbia, MO	MS	2004	BioMedical Sciences G.P.A.: 4.0
University of Missouri-Columbia Columbia, MO	PhD	2007	Pathobiology—Epigenetic modification of radiosensitivity G.P.A: 4.0

Other education:
Provost's Leadership Program, 2022
Post-Doctoral Fellowship in Informatics, National Library of Medicine, July 2005-2007
University of Tennessee Nuclear Medicine Short Course, May 2003
Storz Advanced Laparoscopy Course, July 2000
Storz Basic Endoscopy and Laparoscopy Course, November 1998

Administrative Roles:

Associate Department Chair for Research and Graduate Studies and Multispecies Sections. Veterinary Medicine and Surgery, University of Missouri. 2022-present

Responsibilities
Development of research capabilities, infrastructure, and support in the department with a special focus on expanding clinician science; oversight of Clinical Research Office; mentoring and oversight of multispecies sections in the Veterinary Health Center

Achievements
Created a Clinical Research Office to support clinical studies and trials throughout the department
Hired 1.5 FTE research support for the department to facilitate clinical research
Negotiated a statistical support contract with the Biostatistics Unit of the School of Medicine
Assisted in space allocation and relocation to facilitate research close to the VHC
Assisted in acquisition of equipment (*e.g*. freezers, gel imaging camera, real-time PCR machine)
Chaired a committee to draft a white paper on rejuvenation of clinician science in the department
Budget development for the department
Mentored junior faculty to launch clinical research projects
Mentored mid-career faculty to focus on improved productivity and leadership development
Rejuvenated radiology search to reconstitute the section for the future

Section Head of Oncology. Veterinary Medicine and Surgery, University of Missouri. July 2011-present

Responsibilities
Lead the comprehensive oncology service established in 1998; set priorities through consensus-building; identify resources necessary to meet mission goals; evaluate faculty and guide pre-tenure decisions; allocate research resources equitably; fiscal management of research resources; lead staff supervisor and support staff development and discipline as needed; lead weekly section meetings for ongoing team and consensus building; direct the medical oncology residency and ensure full engagement of faculty in residency training

Achievements
Organized one of only a very few comprehensive oncology services in the country
Directed nursing staff in managing fiscal organization of the section including cost-accounting
Led faculty searches to rebuild the section post-pandemic, attracting 8 entirely qualified applicants to 3 open positions with 3 successful hires
Directed the residency program with a 100% first-time board pass rate and certification rate since becoming program director
Garnered donated funds to remodel the rounds room for teaching and clinical discussions
Garnered over $300,000 donated funds to support resident and faculty research
Recruited staff and doctors from around the country
Diligently expanded service productivity and income annually

Associate Director of Comparative Oncology and Translational Medicine. Ellis Fischel Cancer Center. January 2020-present

Responsibilities

Lead the Comparative Oncology and Translational Medicine priorities for the cancer center, including arranging lecture series; developing ideas laboratories; coordinating research collaborations; supporting investigators in pursuing funding opportunities; facilitating the use of large animal and comparative models of cancer in MU research; managing the pillar budget

Achievements
Initiated comparative oncology lecture series
Collaborated in the development of Oncopig models of lung, pancreas, liver, and brain cancer
Secured an R01 supplement grant to develop canine cancer immunotherapy (CAR-T) as a translational model for human disease, including live-cell tracking technology
Coordinated Oncopig imaging between the ARC, VHC, and NextGen facility for model development
Presented comparative canine cancer models at MD Anderson Pediatric Oncology Grand Rounds
Coordinated joint DVM, MD oncology journal club

Director of the PET Imaging Center. College of Veterinary Medicine and Molecular Imaging and Theranostics Center, University of Missouri. 2018-present

Responsibilities
Wrote and coordinated the request to the Provost's Office for $3,135,000 to purchase the Canon Celesteion PET/CT camera in Clydesdale Hall and establish PET chemistry capabilities at MURR; oversight of the operation of the PET/CT camera and supervision of the Nuclear Medicine Technologist who runs the camera; serve as Authorized User for all PET and some therapeutic isotopes in the VHC; negotiate with Canon for research support for expanded utilization of the camera; manage the budget of the center and encourage use of the technology

Achievements
Camera has been calibrated for 5 isotopes, more than any other clinical scanner in mid-Missouri
Facilitated more than 10 extramurally funded studies utilizing PET imaging in multiple disciplines
Garnered funding for dual HPLC machines, arterial autosampler, and phantoms for calibration to support novel tracer development
Radioembolic preclinical work of Eye90® translated to FDA trials in humans

Faculty Research Lead Cancer Research, NextGen Precision Health. University of Missouri. April 2020-July 2021

Responsibilities
Organize and coordinate the cancer research effort and direction for the NextGen Precision Health effort; participate in the design of the NextGen building; identify campus research strengths; negotiate buy-in from stakeholders in cancer research across colleges of medicine, veterinary medicine, engineering, and arts and sciences; participate in setting standards for building occupancy; identify researchers to be the "NextGen-nauts" as first building occupants; reported directly first to Provost Ramchand and later to Vice Chancellor Barohn

Achievements
Contributed to a physically beautiful and highly functional research building
Built consensus between basic researchers, comparative researchers, and MD oncologists to create a coherent and unified research strategy
Articulated a governance structure
Designed a radiation isolation facility in NextGen to support radiopharmaceutical research

Gave multiple media interviews to articulate the vision and opportunity of NextGen
Chaired committee to draft campus strategy for enhanced cancer research

Director of the Scott Endowed Program in Oncology. University of Missouri. 2013-present

Responsibilities
Administer the funds of the Scott Endowed Program founded by the Scott family in 2004; set vision for the utilization of those funds; ensure that the program benefits cancer research in the section equitably

Achievements
Supported resident research annually since prior to 2011, many projects of which won national research awards
Supported resident and faculty travel annually to present research at national and international scientific meetings
Supported clinical training of veterinary assistants to become Registered Veterinary Technicians
Maintained donor outreach prior to the pandemic
Supported major equipment purchases inside and outside the CVM

Director of the Comparative Radiobiology Oncology and Epigenetics Laboratory. College of Veterinary Medicine. July 2011-September 2019, October 2021-July 2025

Responsibilities
Manage the staff, facilities, and biosafety approvals of the laboratory; approve expenditures and manage the research budget of the laboratory; negotiate for shared resources as needed to support investigator goals

Achievements
Multiple oncology residents have won research awards in the laboratory program
Laboratory operates and maintains multiple shared resource equipment for broad investigator access
Laboratory has continuously conducted extramurally funded research since before 2011
Laboratory supported the cancer tissue banking effort of the campus and the Comparative Oncology Trials Consortium (COTC) of which our group is a founding member
Laboratory supports clinical trials of the COTC and MU is a top enroller nationally

President of the Veterinary Cancer Society. January 2022-December 2024

Responsibilities
Administer the budget of the Veterinary Cancer Society, an international organization of members; define the vision for the society with stakeholders on the Executive Committee and the membership; communicate the decisions of the Executive Committee and the direction of the society to the membership in person and by electronic communication; address member concerns to ensure the society is meeting the needs of the membership; build consensus among the membership around controversial decisions in a shifting political landscape.

Achievements
Engaged members when a rescheduled annual conference from the pandemic was planned in Florida
Built consensus to move forward with the conference, addressing the concerns of groups adversely impacted by newly enacted statutes

Built consensus to embark on a strategic planning effort focused on inclusion and belonging in the organization
Developed guidelines for inclusive excellence for the organization
Administered the transition from a longtime executive director to a new director including successful contract negotiations

President of Oncology, American College of Veterinary Internal Medicine. January 2013-December 2016

Responsibilities
Develop policy for the specialty of Oncology; oversee the development, administration, and scoring of the board examination; address concerns of the constituent members of the specialty of Oncology; balance the needs of the specialty with the needs of the other specialties and college at large in the Board of Regents; execute a fiduciary responsibility to the organization of the ACVIM and evaluate finances and operations with integrity; set vision for the specialty of Oncology in the climate of challenges of the time.

Achievements
Enacted updated residency training requirements in the specialty to address the evolving technology of oncology
Addressed the shared concern of the specialty for workforce needs in oncology through enhanced residency training oversight
Mediated the closure of underperforming programs to address the needs of the residents and the diplomates
Evaluated future challenges in the specialty and articulated prudent responses to the constituent members of the specialty

Medical Director, Irving Street Veterinary Hospital. San Francisco, CA. June 1995-June 2002

Responsibilities
Lead a private small animal/exotic practice; set visionary growth; supervise the staff doctors; assess the financial health regularly; set priorities for growth directions to respond to trends in veterinary practice; grow the practice annually (expected); oversee staff hiring, discipline, education, and duty assignment; address and manage client complaints; oversee the facility

Achievements
Grew the practice from a 1.5 doctor $600,000/year practice to a 4 doctor $1,800,000/year practice
Introduced laparascopic surgery to the San Francisco veterinary market
Oversaw two phases of growth and remodel to handle the expanding doctor staff
Managing doctor for the transition from paper to electronic medical records
Developed local media presence to market and grow the practice

Advancement Activities:
Key Gifts
McCosh Gift to contribute to and name the Pops & Tango PET Imaging Suite ($30,000) was arranged with a grateful client of the Oncology Service of the Veterinary Health Center.
Canney Gift to support the isolation room ($10,000) was arranged with a grateful client of the Oncology Service and Internal Medicine Service of the Veterinary Health Center.

Watson Estate Gift - made introduction to advancement staff leading to a major gift (Unknown $) arranged with a grateful client of the Oncology Service of the Veterinary Health Center.

Civetta Gift to establish the Jasper's Legacy of Love endowment ($25,000) was arranged through a fellow oncologist representing a New York family wanting to support research in a particular canine cancer.

Palmer Gift to establish the Oscar the Dog Fund ($25,000 to date) arranged with a grateful client of the Oncology Service of the Veterinary Health Center. This fund supports fee for service care for patients of the Oncology Service.

Oncology Support Fund has received over $300,000 in donations since 2011.

Professional Experience:

University of Missouri – Professor of Oncology. September 2018-present
University of Missouri – Associate Professor of Oncology. July 2011-August 2018
University of Missouri—Interim Director of the Scott Endowed Program in Oncology. 2012-2013
Washington State University – Assistant Professor of Oncology. July 2007-July 2011
University of Missouri – Research Assistant Professor. July 2005-June 2007
University of Missouri – Oncology Resident. July 2002 – June 2005
Director of Rabbit Health, Maui Animal Rescue and Sanctuary (MARS). October 2000 - 2004
Associate Veterinarian, Irving Street Veterinary Hospital, San Francisco, CA. June 1993 – June 2002
Relief Veterinarian, San Francisco Zoological Gardens. 1994 – 2002

Licenses to Practice Veterinary Medicine:

California: License No. 11833
Missouri: License No. 2002019042

Certification:

Field	Conferring Institution or Board	Date
Oncology	American College of Veterinary Internal Medicine	July 2005

Other Certification:

Field	Conferring Institution or Board	Date
Veterinary acupuncture Certificate Number 00664	International Veterinary Acupuncture Society (IVAS)	March 1995

Awards and Honors:

European Journal of Nuclear Medicine and Molecular Imaging Physics Best Paper 2023
VM4 Golden Aesculapius Award, College of Veterinary Medicine: May 8, 2018.
Dean's Impact Award, University of Missouri, College of Veterinary Medicine: May 18, 2016.
Zoetis Award for Veterinary Research Excellence, University of Missouri: May 10, 2016.
Mentor of AKC CHF Clinician-Scientist Fellowship award winner Dr. Shirley Chu: November 2015.
Technology in Teaching, nominee, University of Missouri: 2013.
Jerry Newbrey Teaching Scholar, College of Veterinary Medicine, Washington State University: 2011.
Norden (Pfizer) Distinguished Teacher Award, Washington State University, College of Veterinary Medicine: April 23, 2010.
Invited Commencement Speaker, Washington State University, College of Veterinary Medicine: May 10, 2009.
Wescott Clinical Teaching Scholar, College of Veterinary Medicine, Washington State University: 2008, 2009, 2010, 2011.

Post-Doctoral Fellowship in Informatics, National Library of Medicine: 2005, 2006, 2007.
First Place, Technology Development Category, Missouri Life Sciences Week: 2005.
First Place Award for Abstract Presentation, Phi Zeta Research Day at the University of Missouri College of Veterinary Medicine: 2004.
University of Missouri College of Veterinary Medicine Redhage Award for Good Client Relations, Veterinary Medical Teaching Hospital: 2003, 2005.
University of Missouri College of Veterinary Medicine Resident Teaching Award: 2003, 2004, 2005.
E. Gregory MacEwen Memorial Award for the Outstanding Basic Research Project in Oncology, awarded by the Veterinary Cancer Society: 2003.
Ivan Award in Veterinary Oncology, Veterinary Medical Teaching Hospital, College of Veterinary Medicine, University of Missouri: 2003.
First Place Award for Abstract Presentation, Phi Zeta Research Day at the University of Missouri College of Veterinary Medicine: 2003.
Pitman-Moore Surgical Scholarship, University of California, Davis, CA: 1993.
Beckye Austin Memorial Scholarship, University of California, Davis, CA: 1990, 1991, 1992, 1993.
Dean's List, College of Agriculture & Environmental Sciences, University of California, Davis, CA: 1986, 1987, 1988, 1989.

Mentoring:

Faculty:

Eva Ulery	Clinical Instructor
Brian Torres	Assistant Professor (now tenured Associate)

Residents:

Chelsea Tripp	Oncology Resident 2007-2010 (Advisor) (Board certified 2010)
Christie Anderson	Oncology Resident 2008-2011 (Board certified 2013)
Kevin Choy	Oncology Resident 2010-2011 (Board certified 2017)
Chamisa Herrera	Oncology Resident 2011-2014 (Advisor) (Board certified 2015)
Brooke Fowler	Oncology Resident 2011-2013 (Board certified 2013)
Katie Fitzpatrick	Oncology Resident 2011-2014 (Did not complete)
Brian Flesner	Oncology Resident 2011-2015 (Board certified 2014)
Lindsay Donnelly	Oncology Resident 2012-2015 (Board certified 2015)
Kim Menard	Oncology Resident 2014-2017 (Board certified 2018)
Shirley Chu	Oncology Resident 2014-2018 (Advisor) (Board certified 2020)
Katie Robinson	Oncology Resident 2015-2018 (Advisor) (Board certified 2019)
Sarah Rippy	Oncology Resident 2015-2018 (Advisor) (Board certified 2019)
Sessaly Reich	Oncology Resident 2017-2021 (Advisor) (Board certified 2021)
Carissa Norquest	Oncology Resident 2017-2020 (Board certified 2022)
Jason Couto	Oncology Resident 2018-2021 (Board certified 2023)
Alyssa Przydrozny	Oncology Resident 2019-present (Advisor) (Board certified 2023)
Lauren Ross	Oncology Resident 2019-present (Board certified 2023)
Kaitlan Hovis	Oncology Resident 2020-present (Board certified 2023)
Caitlin Cowan	Oncology Resident 2020-present (Board certified 2023)
Andrea Montano	Oncology Resident 2021-2022 (discontinued)
Shannon Remerowski	Oncology Resident 2021-2022 (discontinued)
Christine Tran-Hoang	Oncology Resident 2022-2025 (Board certified 2025)
Kristin Sawyer	Oncology Resident 2022-2025 (Advisor) (Board certified 2025)
Katherine Olson	Oncology Resident 2022-2025 (Advisor) (Board certified 2025)
Allison Barbour	Oncology Resident 2022-present

Allison Naclerio	Oncology Resident 2023-present
Vivian Yang	Oncology Resident 2023-present
Laura Yannai	Oncology Resident 2023-present
Allison Valentijn	Oncology Resident 2024-present
Rachel Hritz Mosley	Oncology Resident 2025-present (Advisor)
Bridgette Rogers	Oncology Resident 2025-present (Advisor)
Miranda McBeath	Oncology Resident 2025-present

Interns (Advisor):

Johanna DeKing	Small Animal Rotating Intern 2009-2010
Ana Costa	Small Animal Rotating Intern 2010-2011 (Internist)
Stephanie Byrne	Small Animal Rotating Intern 2011-2012 (Oncologist)
Samuel Hocker	Small Animal Rotating Intern 2012-2013 (Oncologist)
Shirley Chu	Small Animal Rotating Intern 2013-2014 (Oncologist)
Sarah Rippy	Oncology Intern 2013-2014 (Oncologist)
Brittany Evans	Small Animal Rotating Intern 2015-2016 (Oncologist)
Caroline Wood	Small Animal Rotating Intern 2015-2016 (Oncologist)
Karen Koo	Small Animal Rotating Intern 2016-2017 (Oncologist)
Kaitlan Hovis	Small Animal Rotating Intern 2019-2020 (Oncologist)
Shannon Remerowski	Small Animal Rotating Intern 2020-2021
Katherine Olson	Small Animal Rotating Intern 2021-2022 (Oncologist)
Anna Winner	Small Animal Rotating Intern 2022-2023
Allison Barbour	Oncology Clinical Trials Intern 2022-2023 (Oncology Resident)
Allison Valentijn	Oncology Clinical Trials Intern 2023-2024 (Oncology Resident)
Rachel Mosley	Oncology Clinical Trials Intern 2024-2025 (Oncology Resident)
Morgan Tarnalicki	Oncology Clinical Trials Intern 2025-2026

Graduate Students:

Marina Antonio	PhD Student 2008-2012 (complete)	Committee Member
Chelsea Tripp, DVM	Masters Student 2007-2010 (complete)	Advisor
Armando Villamil, DVM	PhD Student 2005-2009 (complete)	Committee Member
Carmela Pratt	Masters Student 2008-2011 (complete)	Committee Member
Jessie Nedrow-Byers	PhD Student 2008-2012 (complete)	Committee Member
Lindsay Donnelly	Masters Student 2011-2013 (complete)	Advisor
Brian Flesner	Masters Student 2011-2014 (complete)	Advisor
Brooke Fowler	Masters Student 2010-2013 (complete)	Advisor
Stephanie Knapp	Masters Student 2011-2015	Committee Member
Melanie Spoor	Masters Student 2011-2012 (complete)	Committee Member
Chamisa Herrera	Masters Student 2012-2019 (complete)	Advisor
Natalie Hoeppe	Masters Student 2011-2014 (complete)	Committee Member
Sarah Hansen	Masters Student 2012-2015 (complete)	Advisor
Tamila Stott Reynolds	PhD Student 2013-2017 (complete)	Committee Member
Tamara Hancock	Masters student 2011-2014 (complete)	Committee Member
Garima Kushwaha	PhD Student 2013-2015 (complete)	Committee Member
Shirley Chu	PhD Student 2014-2019 (complete)	Advisor
Kahn Saad	PhD Student 2012-2019 (complete)	Committee Member
Jake Moskowitz	PhD Student 2016-2019 (complete)	Committee Member
Katie Robinson	Masters student 2015-2018	Committee Member
Sarah Rippy	Masters student 2015-2018 (complete)	Advisor

Tara Piech	Masters student 2015-2017 (complete)	Committee Member
Scott Kemp	Masters student 2016-2017 (complete)	Committee Member
Scott Kemp	PhD student 2017-2018 (moved)	Committee Member
Ronnie LaComb	PhD student 2015-2019 (complete)	Committee Member
Sessaly Reich	PhD then MS student 2017-2021 (complete)	Advisor
George Chingurande	PhD student 2017-present	Committee Member
Elizabeth Schaeffer	Masters student 2016-2019 (complete)	Committee Member
Kate Shumway	Masters student 2017- present	Committee Member
Nattapon Thanintorn	PhD student 2017-2018 (complete)	Committee Member
Alexia Stuckel	PhD student 2018-2019 (complete)	Advisor
Alyssa Przydrozny	Masters student 2019-present	Committee Member
Hayley Ashworth	Masters student 2019-2022 (complete)	Committee Member
Lauren Ross	Masters student 2019-present	Advisor
Christa Cheatham	PhD student 2023-present (complete)	Committee Member
Kate Olson	Masters student 2022-2025 (complete)	Advisor
Kristin Sawyer	Masters student 2022-2025 (complete)	Advisor
Christine Tran-Hoang	Masters student 2022-present	Advisor
Vivian Yang	Masters student 2023-present	Committee Member
Rachel Hritz Mosley	Masters student 2025-present	Advisor
Bridgette Rogers	Masters student 2025-present	Advisor

Intern Seminar (WSU):		Seminar Topic
Ashley Nichols	Discussant	Bisphosphonates
Melanie Spoor	Discussant	Regulatory T-cells
Martha Delaney	Discussant	Cancer Associated Viruses
Alison Book	Discussant	Cancer Immunotherapy

Senior Veterinary Students (WSU):		Senior Paper Topic
Melissa Gaywont	Advisor	Silymarin
Christina Lock	Discussant	Radial Hemimelia in Cats
Sabrina Scrivens	Discussant	Osteosarcoma
Ronald Barringham	Discussant	Lasers in Vet Med
Casey Carl	Discussant	Tricyclic Antidepressants
Andrea Hoover	Discussant	Vascular Endothelial Growth Factor
Betsy LaCroix	Discussant	Stem Cell Transplantation
Sarah Perigo	Advisor	Feline Vaccine Sarcomas
Catherine Walters	Advisor	Cancer Angiogenesis, Anti-Angiogenesis Strategies
Cat Sayer	Discussant	Surgical Treatment of Intrahepatic Portosystemic Shunts
Lori Stokes	Discussant	Adrenal Disease in Ferrets
Liz Ritzenhaler	Discussant	Massage Therapy
Zachary Anderson	Discussant	Feline Arterial Thromboembolism & Bronchoalveolar Carcinoma
Justin Miller	Advisor	Canine Cutaneous Mast Cell Tumors
Megan Breit	Advisor	Demodicosis and the Immune System
Danielle Tulloss	Discussant	Idiopathic Canine IMHA
Jennifer Reagan	Advisor	*Encephalitozoon cuniculi*
Cheryl Thur	Advisor	Electrochemotherapy
Carolina Allende	Discussant	Diagnostics in Lymphoma
Erin Mc Gillic	Discussant	Small Animal Limb Prosthetics

Hillary Nauss	Discussant	Fish Parasites
Melissa Wu	Advisor	Feline Mast Cell Tumors
Vanessa Rucker	Discussant	Pug Encephalitis
Gordon Armstrong	Advisor	Canine Limb Spare
Nikki Graf	Discussant	Chronic Pain
Aimee Ratzlaff	Advisor	Osteosarcoma/Coccidiomycosis Lesions
Stephanie Byrne	Advisor	Immunohistochemistry
Erika Nelson	Advisor	Complementary and Alternative Medicine
Megan Whisler	Advisor	Gender differences in compensation
Jillian Cyrus	Advisor	Comparative Oncology
Jay Huang	Discussant	Reptile Dermatology
Abby Burgess	Discussant	Acute Tumor Lysis Syndrome
Melanie Robinson	Advisor	Chemotherapy for Lymphoma
Brian Hur	Discussant	Electronic Medical Records
Ashley L Brandes	Discussant	Hematopoietic Stem Cell Transplants
Elaina Turba	Discussant	Phantom Limb Pain in Veterinary Medicine
Lisa Gorman	Advisor	Intracavitary and Intralesional Chemotherapy
Ainsley Bone	Discussant	*Wolbachia* in Heartworm Disease
Sara Schrag	Advisor	Melanoma Vaccine
Mark Schrag	Discussant	Feline Analgesia

Veterinary Students (MU):

Jessica Mautone	Advisor	Veterinary Research Scholar
Leah Fray	Advisor	Veterinary Research Scholar
Lucie Noall	Co-advisor	Veterinary Research Scholar
Olivia Hritzkowin	Advisor	Veterinary Research Scholar
Jessica Warwick	Co-advisor	Veterinary Research

Undergraduates:

Janel Brown (Honors College)	Discussant	Veterinary Forensics (WSU)
Zachary Scott	Advisor	Pre-Vet Scholar
Nicholas Noto	Advisor	Pre-Vet Scholar
Shirin Felfeli	Advisor	Pre-Vet Scholar
Tanner May	Advisor	Hughes Research Apprenticeship
Austin Jacobs	Advisor	Pre-Vet Scholar
Jessica Klasing	Advisor	Pre-Vet Scholar
Hannah Sweetwood	Advisor	Pre-Vet Scholar
Joshua Plessner	Advisor	Pre-Vet Scholar
Luciano Rolando	Advisor	Pre-Vet Scholar
Erica Byers	Advisor	Pre-Vet Scholar
Samantha Doisy	Advisor	Summer Undergraduate Research Scholar
Meredith Ash	Advisor	Summer Undergraduate Research Scholar

Service:

Department:

Member, Hospital Advisory Board, 2024- present
Member, Wentzville Oncology Search Committee, 2024.
Member, Non-Tenure Track Promotion Committee, VMS 2023-2024
Member, VMS Research Committee, 2021-present

Member, Promotion and Tenure Committee, VMS, 2021-2024
Chair, Committee to Review Work Load, Veterinary Medicine and Surgery, 2020-2021
Member, Non-Tenure Track Promotion Committee, MU-CVM 2019-2022
Member, Radiology Search Committee, 2015. Successful search.
Member, Soft-tissue Surgery Search Committee, 2016. Successful search.
Member, Oncology Search Committee, 2017, 2021. Successful searches.
Member, Ophthalmology Search Committee, 2017. Successful search.
Member, Radiology Search Committee, 2019.
Member, Wentzville Oncology Search Committee, 2020. Successful search.
Member, Doctoral Faculty Committee, Veterinary Medicine and Surgery, 2015-2016
Chair, Doctoral Faculty Committee, Veterinary Medicine and Surgery, 2013-2015
Member at Large, Hospital Advisory Board, 2012-2022
Member, Research Committee, WSU Veterinary Clinical Sciences Department, 2009-2011
College:
Member, Faculty Responsibility Committee, 2019-2024
Member, College Diversity Committee, 2018-present
Member, Promotion and Tenure Committee, College of Veterinary Medicine 2016-2019
Member, NTT Promotion Committee, College of Veterinary Medicine 2018-present
Member, Administrative Evaluation Committee, College of Veterinary Medicine 2016-present
Member, Research Committee, College of Veterinary Medicine, 2012-2017
President, Pi Chapter of Phi Zeta, University of Missouri, 2013-2014
Student Chapter of the American Association of Zoo Veterinarians, Advisor, 2004-2007
University:
Chair, Think Tank for Cancer Basic Research, 2021-2022
Member, Radiation Safety Committee, 2020-2023
Member, Interdisciplinary Workgroup for Research Support and Infrastructure, 2020
Member, NextGen Precision Health Institute Phase II Committees, 2019-present
Faculty & Research Sub-Committee
Executive Committee for the Integration of Operations, Faculty & Research and External Relations
Operations Sub-Committee
Member, Dean's Advisory Committee on Tissue Banking, MU-SOM, 2018-present
Member, MURR Ombudsman Program. 2018-Present
Director, PET Imaging Center. 2016-present.
Member, Institute for Nano- and Molecular Innovation Committee, 2018-present
Chair, Cancer Research Committee for the TPMC, 2018-2019
Chair and Judge, Research Poster Competition, Comparative and Translational Medicine, Missouri Life Sciences Week, 2019
Judge, Research Poster Competition, Systems Biology, Modeling, and Technology Development Category, and Bioengineering and Informatics, Missouri Life Sciences Week, 2006, 2007, 2013, 2014
Judge, Research Poster Competition, Inaugural One Health Conference, St. Louis Zoo, 2016
Judge, Research Poster Competition, Mizzou Epigenetics Symposium, 2016
University of Missouri Raptor Rehabilitation Project, Advisor, 2004-2007
Grant Reviewer, University of Missouri Research Board, 2007, 2008, 2013, 2015, 2018
Profession:
President-elect, Veterinary Cancer Society, 2020-present.
Member, Board of Directors, Cancer Research Center, Columbia, MO, 2019- present.
Member, Scientific Advisory Board, ELIAS Animal Health, Olathe, KS, 2019- present.

President of the Specialty of Oncology, ACVIM, 2013-2016
President-elect of the Specialty of Oncology, ACVIM, 2010-2013
Co-Chair, Strategic Planning Committee for Research, ACVIM, 2015-2016
Member, American College of Veterinary Internal Medicine Board of Regents, 2010-2016
Chairman, Tissue Distribution Committee, Canine Comparative Oncology & Genomics Consortium, 2010-2016
Member, Review Committee for the Comparative Oncology Trials Consortium-Pharmacodynamic Core, 2010-2017
Member at Large, Veterinary Cancer Society Executive Board, 2008-2011
Member, General Examination Committee, American College of Veterinary Internal Medicine, 2007-2009
Oncology Topic Coordinator, AVMA Annual Convention, Atlanta 2010, St. Louis 2012, San Diego 2013
Abstract Reviewer, Oncology, American College of Veterinary Internal Medicine Forum 2006, 2007
Abstract Reviewer, Veterinary Cancer Society, 2009
University of California, Davis, VMTH External Advisory Committee, Member, 2001-2002
Editorial Board, *Chimerism*, 2016-2017
Manuscript Reviewer, *American Journal of Veterinary Research*, 2007, 2008, 2018
Manuscript Reviewer, *Biology of Blood and Bone Marrow Transplantation*, 2008
Manuscript Reviewer, *BMC Veterinary Research*, 2013, 2014
Manuscript Reviewer, *Canadian Veterinary Journal*, 2009
Manuscript Reviewer, *Cancer Biotherapy and Radiopharmaceuticals*, 2015
Manuscript Reviewer, *Cancer Immunology and Immunotherapy*, 2010
Manuscript Reviewer, *Cell Biology International*, 2013, 2014
Manuscript Reviewer, *Chimerism*, 2016
Manuscript Reviewer, *Clinical Cancer Research*, 2024, 2025
Manuscript Reviewer, *International Journal of Veterinary Medicine*, 2009
Manuscript Reviewer, *International Laboratory Animal Research Journal*, 2014
Manuscript Reviewer, *Journal of Nuclear Medicine*, 2008-2010, 2013
Manuscript Reviewer, *Journal of the American Animal Hospital Association,* 2007- 2016
Manuscript Reviewer, *Journal of the American Veterinary Medical Association,* 2007-2012, 2014, 2015
Manuscript Reviewer, *Journal of Veterinary Internal Medicine*, 2007- 2011, 2013-2025
Manuscript Reviewer, *Journal of Veterinary Medical Science*, 2011
Manuscript Reviewer, *Journal of Veterinary Medicine Series A,* 2006
Manuscript Reviewer, *Journal of Veterinary Pharmacology and Therapeutics,* 2019
Manuscript Reviewer, *Journal of Zoo and Wildlife Medicine,* 2007, 2010
Manuscript Reviewer, *Molecular Imaging and Biology*, 2015
Manuscript Reviewer, *Oncogene*, 2010
Manuscript Reviewer, *PLoS One*, 2011-2014,2018,2021,2022
Manuscript Reviewer, *The Prostate*, 2016
Manuscript Reviewer, *Radiochimica Acta*, 2019
Manuscript Reviewer, *Theranostics*, 2016
Manuscript Reviewer, *Veterinary Medicine and Science,* 2015, 2016
Manuscript Reviewer, *Veterinary Medicine International,* 2009
Manuscript Reviewer, *Veterinary and Comparative Oncology,* 2010, 2013, 2014, 2016,2020-25
Manuscript Reviewer, *Veterinary Pathology,* 2013, 2014
Manuscript Reviewer, *Veterinary Pharmacology and Therapeutics,* 2019
Manuscript Reviewer, *Veterinary Record,* 2007, 2009

Grant Reviewer, Washington State University Cancer Prevention and Research Center, 2008.
Grant Reviewer, University of Washington in St. Louis ICTS, 2016-2018.
Grant Reviewer, The Canine Health Foundation, 2019.

Membership in Professional Organizations:
National Association of Black Veterinarians, 2020-present
American College of Veterinary Internal Medicine, 2002-present
Veterinary Cancer Society, Member, 2001-present
Radiopharmaceutical Sciences Institute, University of Missouri, 2011-present
Institute of Clinical and Translational Sciences, Washington University in St. Louis, 2015-present
Genetics Area Program, University of Missouri, 2018-present
Center for Integrated Biotechnology, Washington State University, 2007-2009
Cancer Prevention and Research Center, Washington State University, 2007-2009
American Association for the Advancement of Science, Member, 2007-present
Society of Phi Zeta, Member, 1993-present
American Veterinary Medical Association, Member, 1993-2019, 2024-present
Washington State Veterinary Medical Association, 2007-2010
Association of Avian Veterinarians, Member, 1993-2004
Association of Reptile and Amphibian Veterinarians, Member, 1993-2002
International Veterinary Acupuncture Society (IVAS), Member, 1995-2004

Research Support:
Lattimer JC (PI), Kunz DA (Co-I), **Bryan JN (Co-I)**. Preliminary study of treatment of osteomyelitis with ^{153}Sm-EDTMP. Granted by Dow Chemical Co. **$1,000**. 07/01/02-07/01/03.

Bryan JN (PI), McCaw DL (mentor). Proteomic comparison of circulating and nodal lymphocytes in normal dogs. Granted by the Society of Phi Zeta, University of Missouri College of Veterinary Medicine Phi Zeta Research Day Proposal. **$750**. 01/01/03-04/01/03.

Bryan JN (PI), Lewis M (Co-PI). Copper-64-labeled antibodies for radioimmunotherapy of cancer. Granted by the University of Missouri, College of Veterinary Medicine Committee on Research. **$6,000**. 01/01/03-06/30/04.

Volkert W (PI, Radiology), $6,937,979 direct; Lewis MR (Co-PI, Research Component PI, and Project Leader) (20%), with Hannink M (Co-I, Biochemistry), Henry CJ (Co-I, Veterinary Medicine and Surgery), Lattimer JC (Co-I, Veterinary Medicine and Surgery), Singh A (Co-I, Radiology), Lever S (Collaborator, Chemistry), Jia F (I, Veterinary Medicine and Surgery), and **Bryan JN (I, Veterinary Medicine and Surgery).** Development of new peptide-peptide nucleic acid conjugates for i*n vivo* imaging of *bcl-X_L* expression in lymphoma. Center for Single Photon-Emitting Cancer Imaging Agents. National Cancer Institute. $648,125 direct, 07/01/03 - 06/30/08; Development of radiolabeled PNAs for targeting a split transcription factor involved in the UPR response in breast cancer. Lewis MR (Co-I) (2%), with Hannink M (Co-PI and Development Project PI, Biochemistry). $44,834 annual direct, 07/01/03 - 06/30/08.

Bryan JN (PI), DL McCaw (Co-I), S Alexander (Co-I). Proteomic evaluation of total lymphocyte proteins and membrane-bound proteins of lymphocytes from a boxer dog with chronic lymphocytic leukemia. Tom and Betty Scott Endowed Program in Veterinary Oncology. **$1,568**. 06/01/04-06/01/05.

Henry CJ (PI), McCaw DL (Co-I), Selting KA (Co-I), **Bryan JN (Co-I),** Johnson KD (Co-I), A study to assess the efficacy and safety of ML-1,785,713 oral chewable tablets alone and in combination with cisplatin in dogs for the treatment of transitional cell carcinoma of the urinary bladder. Merial Limited; 9/30/04-9/30/05; **$120,268** (2% effort, 11% shared credit).

Dhand R (PI), Selting K (Co-I), Waldrep JC (Co-I), Branson K (Co-I), **Bryan JN** (Co-I), Henry C (Co-I), Grueber R (Co-I). Targeted Inhalational Delivery of Chemotherapy via the AeroProbe® Intratracheal Catheter in Dogs. American Respiratory Care Foundation Grant. Amount $10,000 - Phase I. (Awarded: October 2004.)

Tripp CD, **Bryan JN**, Selting KA. Thyroid stimulating hormone (TSH) levels as a predictor for pertechnetate (^{99m}TcO4-) uptake in dogs with thyroid carcinomas. Granted by the Society of Phi Zeta, University of Missouri College of Veterinary Medicine Phi Zeta Research Day Proposal. **$750**. 01/01/05-04/01/05.

Selting KA, Robertson JD, Wang X, Henry CJ, McCaw DL, **Bryan JN**, Johnson KD, Rankin WV, Villamil JA, Owen N, Steffy J. ICP-MS quantification of plasma platinum concentrations following administration of oral Satraplatin for pharmacokinetic analysis. NSEI Reactor Utilization Grant (MU Research Reactor). 9/30/05-9/29/06; **$8000** direct.

Henry CJ (PI) 30% shared credit, 1% effort; Selting KA (Co-I) 15% shared credit; 1% effort; McCaw (Co-I); 15% shared credit; 1% effort; **Bryan JN** (Co-I); 15% shared credit; 1% effort; Pope ER (Co-I) 1% effort; 25% shared credit. Evaluation of RGD targeted delivery of phage expressing TNF-alpha to tumor bearing dogs: Study 1; National Institutes of Health- National Cancer Institute Comparative Oncology Trials Consortium, Bethesda, MD, 03/01/06 – 05/01/06, **$9,173**.

Henry CJ (PI) 30% shared credit, 1% effort; Selting KA (Co-I) 15% shared credit; 1% effort; McCaw (Co-I); 15% shared credit; 1% effort; **Bryan JN** (Co-I); 15% shared credit; 1% effort; Pope ER (Co-I) 1% effort; 25% shared credit. Evaluation of RGD targeted delivery of phage expressing TNF-alpha to tumor bearing dogs: Study 2; National Institutes of Health- National Cancer Institute Comparative Oncology Trials Consortium Bethesda, MD, 05/01/2006 – 09/01/2006, **$28,151**.

Bryan JN (PI), Taylor KH (Co-I), Davis W (Co-I), Caldwell CW (Co-I) Methylation, expression, and cloning of a novel canine cancer gene, DLC1. Department of Veterinary Medicine and Surgery Committee on Research. 6/01/06-05/31/07. **$2,801**.

Bryan JN (PI), Henry CJ (Co-I), Cutler C (Co-I), Ketring A (Co-I), Lattimer JC (Co-I). Systemic toxicity of ^{177}Lu-DOTMP administered intravenously to normal dogs. MU Research Reactor Partnership Initiatives and Scott Endowed Program in Veterinary Oncology. 9/1/06-9/1/07. **$23,887**.

Wills TB(PI), Davis WC(co-PI), **Bryan JN**(co-PI), Fidel JL(co-PI). Evaluating lymphocyte immunophenotypes in canine peripheral blood using flow cytometry and three color analysis. College of Veterinary Medicine Intramural Grant, Washington State University. 9/01/08-7/31/09. **$18,675.00.**

Bryan JN (PI), Jabbes M (Co-I), Tripp CD (co-I). Immunoprecipitation for hypermethylation screening of canine lymphoma cell lines. College of Veterinary Medicine Intramural Grant. 5% FTE. 7/1/08-6/30/09. **$19,668**

Benny P (PI), Berkman C (co-I), **Bryan JN** (co-I)**.** Development of Prostate Membrane Specific Antigen (PMSA) Inhibitors Coupled to $^{99m}Tc(CO)_3^+$ with Enhanced Specific Activity for SPECT Imaging. Department of Energy, DE-PS02-08ER08-11. April 2008. **$622,266.**

Berkman C (PI), Benny P (co-I), **Bryan JN** (co-I)**.** Chemoaffinity Agents for the Detection of Prostate Cancer. Washington State Life Sciences Discovery Fund. 9/1/08-8/31/09. **$332,133.**

Bryan JN (PI). Examination of Canine Lymphoma Cell Lines for CpG Island Hypermethylation by Microarray. American Cancer Society. 1/1/09-12/31/09. **$30,000.**

Tripp CD (PI), **Bryan JN** (mentor). Expression of Lim homeobox (*LHX2*) and Brain 1(*POU3F3*) genes in canine lymphoma cell lines. Veterinary Clinical Sciences Graduate Student Grants. 1/1/09-12/31/09. **$6,999.**

Sasaki T (PI), **Bryan JN** (Co-PI). Development of Artemisinin Compounds for Cancer Treatment. Washington State Life Sciences Discovery Fund. 1/1/10-12/31/12. Award total was $1,451,193 with subcontract total of **$269,146** and $ 232,607 direct.

Bryan JN (Co-PI), DeClue AE (Co-PI), Axiak SM (Co-I). Evaluation of immunological and tumor characteristics defining response to an intravenous infusion of C. novyi-NT for the treatment of melanoma, soft tissue sarcoma or select carcinomas in dogs. BioMed Valley Discoveries. 2/1/12-1/31/14. **$944,538** total funding.

Herrera C (PI), **Bryan JN** (Mentor). Identifying DNA Methylation Marks as Potential Biomarkers for Canine Metastatic Osteosarcoma and Primary Lung Cancer. Phi Zeta Grant. 12/1/11-5/1/12. **$750**

Menning J (PI), **Bryan JN** (Mentor). Vascular Endothelial Growth Factor (VEGF) Levels in Dogs and its Association with Chronic Gingivitis. Phi Zeta Grant. 12/1/11-5/1/12. **$715.50**

Bryan JN (PI), Axiak S (Co-I), Kumar S (Co-I). Initial exploration of fetal microchimerism in golden retrievers. University of Missouri CVM Committee on Research. 2/1/12-1/31/13. **$11,269.04**

Bryan JN, Herrera C, Kumar S, Katti K, Kannan R, Upendran A, Cutler C, Davis W, Bechtel S, Lattimer J, Tate DJ, Dong X, Joshi T. Of Dogs and Men: the Roots of Prostate Cancer. Mizzou Advantage. 1/13-12/15. **$25,000**

Bryan JN (PI), Kumar SR (Co-I). Ellis Fischel Cancer Center Equipment Grant. Nanodrop Spectrophotometer. **$10,000**.

Bryan JN (PI). Phase I/II evaluation of cisplatin hyaluronate nanoparticles in tumor-bearing dogs. Nanopharm LLC. 1/10/13-1/9/16. **$89,442**

Bryan JN (PI), Lattimer JC, Knapp S, Selting KA, Henry CJ, Bechtel-Axiak S. Pilot evaluation of ^{18}F-FDG-PET imaging to stage dogs with lymphoma. CVM Clinician Scientist Award, 2/1/13-1/31/14, **$8000**.

Forrest L (PI), **Bryan JN (Co-I)**. Biomaterial for head and neck cancer treatment. NIH NCI R01. 10/1/12-9/30/17. **$154,002** subaward.

Lattimer J (PI), Selting K (Co-I), Ketring A (Co-I), **Bryan JN** (Co-I), Henry CJ (Co-I), Axiak S (Co-I). A new radiopharmaceutical for the treatment of metastatic bone cancer. NIH SBIR. 7/1/12-6/30/16. **$303,000**.

Bryan JN (Co-PI), Avery A (Co-PI), Wilson-Robles H (Co-PI). Discovery of novel protein, blood, and epigenetic biomarkers of lymphoma risk, classification, and prognosis in Golden Retrievers. Canine Health Foundation. 7/1/13-6/30/16. **$404,814**.

Amos-Landgraf J (PI), **Bryan JN (Co-I)**, Hansen S (Co-I). Development of an in vivo rat model of fetal microchimerism to investigate the susceptibility to early colorectal cancer. University of Missouri CVM Committee on Research. 2/1/14-1/31/15. **$18,000**

Hansen SA (PI), **Bryan JN** (Mentor). Development of equine microchimerism assay to investigate sibling microchimerism. Phi Zeta Grant. 12/1/2013-5/1/2014. **$750**

Fink M (PI), Mohan R (Mentor), **Bryan JN (Co-I)**. Fetal microchimerism in corneal wound healing. Phi Zeta Grant. 12/1/13-5/1/14. **$750**

Bryan JN (Site PI). Preclinical comparison of three indenoisoquinoline candidates in tumor-bearing dogs. Leidos Inc. and COTC. 3/25/14-9/24/15. **$16,294**

Bryan JN (Site PI). Prospective, multicenter, randomized, double-blinded, placebo-controlled, 2-parallel groups, phase 3 study to compare efficacy and safety of masitinib to placebo in the treatment of grade 2-3 non-resectable mast cell tumors in dogs not previously treated by chemotherapy (other than corticosteroids) or radiotherapy. 6/9/14-6/30/16. ($85,015.15 Direct and $22,104 Indirect). **$107,119.15**

Clark GF (PI), **Bryan JN** (Co-I), Henry CJ (Co-I). A novel therapeutic approach for aggressive metastatic cancer. Mizzou Advantage Seed Grant. 6/10/2014-6/9/2016. **$50,000**

Clark GF (PI), **Bryan JN** (Co-I), Henry CJ (Co-I). A method to detect and target aggressive metastatic tumor cells for destruction. Breeden-Adams Foundation. 2/1/2015-1/31/2016. **$30,000**

Bryan JN (lead), Braun D, Jurisson S, Robertson JD and colleagues. PET Imaging Center for the University of Missouri. University of Missouri Office of Research. Begins 6/1/16. **$3,135,000**

Schultz L, Arthur G, **Bryan JN**, Popescu M, Shyu C, Hahn A. The graphical display of historical veterinary cancer data. Ellis Fischel Cancer Center Research Internal Funding Request. **$7,600**

Coates JR (PI), Gerdes JM (Co-PI), **Bryan JN** (Co-I). Temporal Regional PET Imaging of the CNS EAAT2 Protein in Canine Degenerative Myelopathy as a Disease Model of ALS. The Amyotrophic Lateral Sclerosis Association. 8/1/2016-1/31/2019. **$221,585**

Kumar SR, **Bryan JN**. Tivantinib a hepatocyte growth factor receptor inhibitor induces cytotoxicity in human and canine melanoma cells. Faculty Research Award, College of Veterinary Medicine, University of Missouri. **$9,800**

Henry CJ (PI), **Bryan JN (Co-PI)**. Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of Surgery and CANINE-OST-1 as Treatments for Newly Diagnosed Osteosarcoma in Dogs. ELIAS Animal Health, LLC. 5/1/2015-4/30/17. **$208,357**

Maitz CA, **Bryan JN**, Kumar SR. Chemosensitization for osteosarcoma and transitional cell carcinoma using low-dose radiation. Faculty Research Award, College of Veterinary Medicine, University of Missouri. **$15,795**

Axiak-Bechtel SM, Henry CJ, **Bryan JN**, Selting KA. Phase I trial of laser immunotherapy for the treatment of non-resectable canine oral melanoma. Clinician Scientist Grant, College of Veterinary Medicine, University of Missouri. **$7,935**

Flesner B (PI), **Bryan JN** (Co-I), Henry CJ (Co-I), Selting KA (Co-I), Bechtel SB (Co-I). D16CA518-A Contemporaneous controlled study of the standard of care (SOC) in dogs with appendicular osteosarcoma. Morris Animal Foundation. 1/1/16-12/31-18. **$28,080**.

Flesner B (PI), **Bryan JN** (Co-I), Henry CJ (Co-I), Selting KA (Co-I), Bechtel SB (Co-I). D16CA519-A Evaluation of orally administered mTOR inhibitor rapamycin in dogs in the adjuvant setting with osteosarcoma. Morris Animal Foundation. 1/1/16-12/31-18. **$47,628**.

Bryan JN (PI), Henry CJ, Reinero C, Curiel D. Development of viroimmunotherapy for malignant melanoma. Washington University in St. Louis ICTS. 10/19/15. **$50,000**.

Shyiu C-R (PI), Xu D, Shin D, **Bryan JN** (Co-I), Conant G, Middlekoop T. Massive and Complex Data Analytics Pre-Doctoral Training in One Health. National Library of Medicine. 7/1/16-6/30/21. **$1,427,216.**

Katti KV (PI), **Bryan JN (Co-PI)**, Henry CJ (Co-I). From mice to dogs toward clinical translation studies of a new gold nano-therapeutic agent. Ellis Fischel Seed Funding. 7/7/16-7/6/17. **$25,000**.

Moore M, Maitz C, **Bryan JN** (Co-I), Lattimer JC, Kim DY. Oxygenation and volume response of spontaneous canine sarcomas treated with Thermofield 250A electromagnetic hyperthermia and radiation therapy. Veterinary Cancer Society 2017 Resident Research Program. 4/1/17-3/31/18. **$20,000**.

Evanoff B (PI), Parker J (sub PI), **Bryan JN** (Co-I). WU Institute of Clinical and Translational Sciences. 7/1/17-2/28/18 (First award period. Projected to continue through 2/28/21). **$62,169** MU subcontract.

Bryan JN (Co-PI), Hennkens H (Co-PI). Pretargeted PET Imaging of Bone in Canines. Hunter College. 10/1/17-9/30/18. **$33,556** total award.

Bryan JN (PI). Evaluation of Non-Conventional Isotope Imaging Using Celesteion. Canon Medical Systems, USA. 3/1/18-2/28/21. **$34,500** total award.

Flesner BK (PI), **Bryan JN (Co-I)**, Donnelly L (Co-I). Evaluation of a recombinant, attenuated Listeria monocytogenes expressing a chimeric human HER2/neu protein in dogs with osterosarcoma in the adjuvant setting. Morris Animal Foundation. 09/01/17-08/31/19. **$55,728** total award.

Flesner BK (PI), Donnelly LL, McCleary-Wheeler A, Tate DJ, **Bryan JN**. Preclinical Assessment of an oral p97 inhibitor, CB-5339, in Tumor-Bearing Dogs. NCI-COTC 028 sponsored by Leidos Inc. Funded December 2018. **$69,226**.

Maitz CA (PI), **Bryan JN (Co-I)**. 124-I PET to evaluate dosimetry of radioiodine therapy. University of Missouri College of Veterinary Medicine Clinician Scientist Grant. 03/01/18-02/18/19. $**8,000**

Bryan JN (PI), Reich (Resident Mentee). HER2/neu antibody validation in dogs and expression pattern in canine osteosarcoma cell lines and tissues. ACVIM Resident Grant. 1/1/18-21/31/19. **$10,000** direct

Bryan JN (PI). Evaluation of Activated Eye90™ Radioembolic Microsphere radiopacity on CT and signal on MRI in Rabbit Liver VX2 Tumor, evaluation of effect of radiopacity on detection of tumor enhancement on conventional Computed Tomography. ABK Biomedical Inc. 11/1/19-8/31/20. **$305,097 total**

Bryan JN (PI). First in Dog Oncology Trial utilizing Radioembolization Eye90 Advanced Treatment Study (FIDO TREATS). ABK Biomedical Inc. 3/14/21-3/15/22. **$148,773 total**

Griffith OL (PI), **Bryan JN (co-PI)**. Modeling anti-PD1 response and resistance in naturally occurring canine cancer. Siteman Investment Program, Pre-R-01. 01/01/20-12/31/21. **$200,000** direct

Ulery B (PI), Daniels M (co-I), Burke D (co-I), **Bryan JN (co-I)**. Targeted Nanoparticle Therapeutic for the Treatment of Hematological Cancers. Midwest Biomedical Accelerator Consortium. 9/1/20-8/31-21. **$200,000** total.

Bryan JN (Site PI), Flesner BK (Co-I), Donnelly LL (Co-I), McCleary-Wheeler A (Co-I). Novel IL-12 Delivery Vehicles for Transformation of Solid Tumors (subaward of Pollack S, Northwestern University). NIH R01 SP0067224. **$100,085** total funding.
Bryan JN (PI). Ethos PUSH Biospecimen Collection Agreement. Ethos Discovery. 4/13/22-4/12/26. **$85,164** direct.

Chu S (PI), **Bryan JN** (Co-I), Donnelly L (Co-I). Cancer Lifetime Assessment Screening Study in Canines. PetDx. 7/22-7/27. **$41,811** total

Bryan JN (PI). Evaluation of xenogeneic CAR-T cell therapy for canine CD20+ B cell lymphoma. Lifengine Animal Health Laboratories. 06/22-05/27. **$88,068** direct

Bryan JN (PI). EARLIpaws-05CT. Earli Inc. 8/22-7/23. **$157,905** direct

Bryan JN (PI). EARLIpaws-05CT An Open Label, Single Dose Study to Evaluate the Positron Emission Tomography (PET) Imaging Properties of EARLI-201 in Canines with Locally Advanced or Metastatic Cancer and Normal Healthy Dogs. Earli Inc. 8/22-7/23. **$90,654** direct

Bryan JN (PI). Analysis of renal biopsies by University of Missouri, College of Veterinary Medicine. Edge Animal Health. 10/22-9/23. **$15,317**

Bryan JN (Site PI). Comparative Oncology Program COTC033: Repurposing Vaccine Immunity to Treat Cancers Validation in Canine Patients. Guidehouse Inc. 9/23-9/24. **$50,694**

Bryan JN (Site PI). Ethos PUSH (Precision Umbrella Study for Canine Hemangiosarcoma) Biospecimen Collection Agreement. Ethos Discovery. 1/23-1/25. **$68,357**

Bryan JN (PI). Pilot study of anti-canine CTLA4 mAB (VGS-001) in canine patients with state III/IV oral melanoma. Vetigenics. 05/01/2023-04/30/2025. **$109,669 total direct costs**

Bryan JN (Site PI). Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines. Mayo Clinic R01 subaward from National Cancer Institute. 20/23-9/24. **$138,464**

Sgouros G (PI), Kraitchman D (PI), **Bryan JN (Site PI)** Edwards B (co-I). Alpha-Emitter Therapy of Osteosarcoma. National Cancer Institute R01CA285588. 07/2024-06/2029. **$532,230 total.**

Bryan JN (PI), Mickelson M. Clinical trial to evaluate the safety and effectiveness of a vaccine-enhanced adoptive T cell therapy combined with a novel adjuvant following limb-sparing surgery as treatment for appendicular osteosarcoma in dogs. ELIAS Animal Health, LLC. 07/19/2024-01/18/2026. **$155,123 total direct costs**

Bryan JN (PI). biSNA application for immunotherapy of soft-tissue sarcoma. Washington University. 12/2024-11/2025. **$28,682 total.**

Bryan JN (Co-I), Seth Pollack (PI). Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors. NIH R01CA244872 to Northwestern University. 01/2021-12/2025. **$2,467,464 total.**

Bryan JN (PI). Direct lymph node injection of xCAR-T cell therapy in dogs with CD20+ diffuse large B cell lymphoma. Leah Laboratories. 05/2025-04/2026. **$80,820 total.**

Research Consultation:
Maxwell L (PI), Satyanarayana A, Ritchey J, of Oklahoma State University. Allometry of Hepatic Metabolism of Vinblastine in Dogs. Morris Animal Foundation proposal D08CA-066, 9/08-8/10.

Research Collaboration:
Principal Investigator, Washington State University, NCI-CCR COTC Trial Membership, 7/6/09-7/6/11

Principal Investigator, University of Missouri, NCI-CCR COTC Trial Membership, 1/1/20-present

Publications:
Refereed Articles:
93) Joshi K, Suvilesh KN, Natesh NS, Manjunath Y, Coberly J, Schlink S, Kunin JR, Prather RS, Whitworth K, Nelson B, **Bryan JN**, Hoffman T, Golzy M, Raju M, Teixeiro E, Telugu BP, Kaifi JT, Rachagani S. Characterization of A Bronchoscopically Induced Transgenic Lung Cancer Pig Model for Human Translatability. *bioRxiv* [Preprint]. 2024:2024.11.04.621940. doi: 10.1101/2024.11.04.621940. PMID: 39569144;

92) Mason NJ, Selmic L, Ruple A, London CA, Barber L, Weishaar K, Perry JA, Mahoney J, Flesner B, **Bryan JN**, Willcox JL, Burton JH, Vail DM, Kisseberth WC, Balkman CE, McCleary-Wheeler AL, Curran KM, Leeper H, Woods JP, Mutsaers AJ, Higginbotham ML, Wouda RM, Wilson-Robles H, Dervisis N, Saba C, MacDonald-Dickinson VS, Hess PR, Cherukuri A, Rotolo A, Beck JA, Patkar S, Mazcko C, LeBlanc AK. Immunological responses and clinical outcomes in pet dogs with osteosarcoma receiving standard of care therapy and a recombinant Listeria vaccine expressing HER2/neu. I. 2025:S1525-0016(25)00113-3. doi: 10.1016/j.ymthe.2025.02.023. Epub ahead of print. PMID: 39955616.

91) Bryan JN, Maitz CA. Translational history and hope of immunotherapy of canine tumors. *Clin Cancer Res.* 2024; doi: 10.1158/1078-0432.CCR-23-2266.

90) Kuroki K, Hoang CT, Rogic AM, Rindt H, Simenson A, Noall LG, **Bryan JN**, Johnson GC, Chu S. Hotspot Exon 15 Mutations in BRAF Are Uncommon in Feline Tumours. Vet Comp Oncol. 2024;22:452-456. doi: 10.1111/vco.12997. PMID: 39015955.

89) Joshi K, Telugu BP, Prather RS, Bryan JN, Hoffman TJ, Kaifi JT, Rachagani S. Benefits and opportunities of the transgenic Oncopig cancer model. *Trends Cancer*. 2024;10:182-184.

88) Joshi K, Katam T, Hegde A, Cheng J, Prather RS, Whitworth K, Wells K, **Bryan JN**, Hoffman T, Telugu BP, Kaifi JT, Rachagani S. Pigs: Large Animal Preclinical Cancer Models. *World J Oncol.* 2024;15:149-168.

87) Hoang MH, Skidmore ZL, Rindt H, Chu S, Fisk B, Foltz JA, Fronick C, Fulton R, Zhou M, Bivens NJ, Reinero CN, Fehniger TA, Griffith M, **Bryan JN**, Griffith OL. Single Cell T Cell Receptor Repertoire Profiling for Dogs. *Comms Bio*. 2024;7:484.

86) Maitz CA, **Bryan JN**. The Role of Companion Animal Models in Radiopharmaceutical Development and Translation. *Vet Comp Oncol*. 2024;22:165-173.

85) Wilson EJ, Sirpu Natesh N, Ghadermazi P, Pothuraju R, Prajapati DR, Pandey S, Kaifi JT, Dodam JR, **Bryan J**, Lorson CL, et al. Red Cabbage Juice-Mediated Gut Microbiota Modulation Improves Intestinal Epithelial Homeostasis and Ameliorates Colitis. *International Journal of Molecular Sciences.* 2024; 25:539. https://doi.org/10.3390/ijms25010539

84) Stahlberg EA, Abdel-Rahman M, Aguilar B, Asadpoure A, Beckman RA, Borkon LL, **Bryan JN**, Cebulla CM, Chang YH, Chatterjee A, Deng J, Dolatshahi S, Gevaert O, Greenspan EJ, Hao W, Hernandez-Boussard T, Jackson PR, Kuijjer M, Lee A, Macklin P, Madhavan S, McCoy MD, Mohammad Mirzaei N, Razzaghi T, Rocha HL, Shahriyari L, Shmulevich I, Stover DG, Sun Y, Syeda-Mahmood T, Wang J, Wang Q, Zervantonakis I. Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation. *Front Digit Health*. 2022 Oct 6;4:1007784. doi: 10.3389/fdgth.2022.1007784.

83) Selting KA, Simon J, Lattimer JC, Ketring A, Axiak-Bechtel S, Frank K, Wendt RE, **Bryan JN**, Tate D, Maitz C, Lunceford J, Donnelly L, Keegan K, Henry CJ. Phase I evaluation of CycloSam® (Sm-153-DOTMP) bone seeking radiopharmaceutical in dogs with spontaneous appendicular osteosarcoma. *Vet Radiol Ultrasound*. 2023 Sep;64(5):982-991. doi: 10.1111/vru.13274

82) **Bryan JN.** Updates in Osteosarcoma. *Vet Clin North Am Small Anim Pract*. 2024;54:523-539. doi: 10.1016/j.cvsm.2023.12.007. Epub 2023 Dec 28. PMID: 38158305.

81) Rodney AR, Skidmore ZL, Grenier JK, Griffith OL, Miller AD, Chu S, Ahmed F, **Bryan JN**, Peralta S, Warren WC. Genomic landscape and gene expression profiles of feline oral squamous cell carcinoma. *Front Vet Sci*. 2023;10:1079019. doi: 10.3389/fvets.2023.1079019.

80) Noall L, Lee S, Burton JH, Marquardt TM, Cermak J, Thombs LA, Rogic AM, **Bryan JN**, Chu S. A multi-institutional epidemiologic study evaluating environmental risk factors for feline oral squamous cell carcinoma. *Vet Comp Oncol*. 2023. doi: 10.1111/vco.12914. Online ahead of print.

79) Schaefer EAF, Chu S, Wylie KM, Wylie TN, Griffith OL, Pearce JW, Johnson GC, **Bryan JN**, Flesner BK. Metagenomic analysis of DNA viruses with targeted sequence capture of canine lobular orbital adenomas and normal conjunctiva. *Microorganisms*. 2023;11:1163

78) Fu Y, Yu J, Liatsou I, Du Y, Josefsson A, Nedrow JR, Rindt H, **Bryan JN**, Kraitchman DL, Sgouros G. Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma. *Eur J Nucl Med Mol Imaging*. 2022 Jul 9. doi: 10.1007/s00259-022-05888-5.

77) Shumway KL, **Bryan JN**, Donnelly LL, Flesner BK, Lattimer JC, McCleary-Wheeler AL, Lunceford JM, Maitz CA. Biodistribution and image characteristics of 124 I-positron emission tomography in dogs with neuroendocrine neoplasia. *Vet Radiol Ultrasound*. 2022;63:298-305. doi: 10.1111/vru.13050.

76) Chu S, Avery A, Yoshimoto J, **Bryan JN**. Genome wide exploration of the methylome in aggressive B-cell lymphoma in Golden Retrievers reveals a conserved hypermethylome. *Epigenetics*. 2022;1-17. doi: 10.1080/15592294.2022.2105033.

75) LeBlanc AK, Mazcko CN, Fan TM, Vail DM, Flesner BK, **Bryan JN**, Li S, Wang F, Harris S, Vargas JD, Govindharajulu JP, Jaganathan S, Tomaino F, Srivastava AK, Chou TF, Stott GM, Covey JM, Mroczkowski B, Doroshow JH. Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs. *Mol Cancer Ther*. 2022; doi: 10.1158/1535-7163.MCT-22-0167.

74) Maitz CA, Delaney S, Cook BE, Genady AR, Hoerres R, Kuchuk M, Makris G, Valliant JF, Sadeghi S, Lewis JS, Hennkens HM, **Bryan JN**, Zeglis BM. Pretargeted PET of Osteodestructive Lesions in Dogs. *Mol. Pharm*. 2022;19:3153-3162. doi: 10.1021/acs.molpharmaceut.2c00220.

73) Henry EC, Strugari M, Mawko G, Brewer K, Liu D, Gordon AC, **Bryan JN**, Maitz C, Karnia JJ, Abraham R, Kappadath SC, Syme A. Precision Dosimetry in Yttrium-90 Radioembolization through CT Imaging of Radiopaque Microspheres in a Rabbit Liver Model. *EJNMMI Phys*. 2022;9:21. doi: 10.1186/s40658-022-00447-1.

72) Reising AJ, Donnelly LL, Flesner BK, Maitz CA, **Bryan JN**. Solitary osseous plasmacytomas in dogs: 13 cases (2004-2019). *J Small Anim Pract*. 2021 doi: 10.1111/jsap.13411

71) Ierardi RA, Anderson MN, **Bryan JN**, Matheson JS, Sample SH, Coates JR. Epidural myelolipoma in a Silken Windhound. *J Vet Clin Path*. 2021; DOI: 10.1111/vcp.13090, in press.

70) Yevtodieyenko A, Bazhin A, Khodakivskyi P, Godinat A, Budin G, Maric T, Petramaggiori G, Scherer SS, Kunchulia M, Eppeldauer G, Polyakov SV, Francis KP, **Bryan JN**, Goun EA. Portable

bioluminescent platform for in vivo monitoring of biological processes in non-transgenic animals. *Nat. Comm.* 2021

69) Qi X, Yang M, Ma L, Sauer M, Avella D, Kaifi JT, **Bryan J**, Cheng K, Staveley-O'Carroll KF, Kimchi ET, Li G. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response. *J Immunother Cancer*. 2020;8(2). doi: 10.1136

68) Chu S, Griffith OL, Skidmore ZL, Kunisaki J, Walker JR, Griffith M, **Bryan JN**. Unraveling the chaotic genomic landscape of primary and metastatic canine appendicular osteosarcoma with current sequencing technologies and bioinformatic approaches. PLOS ONE. 2021;16:e0246443. doi: 10.1371/journal.pone.0246443

67) Norquest C, Flesner BK, Maitz CA, **Bryan JN**, Moore M, Ehling T, Lattimer JC. Significantly increased fracture rate in dogs with appendicular osteosarcoma receiving finely fractionated compared to coarsely fractionated radiation therapy: a single institution study. *Vet Comp Oncol*. Submitted 2020.

66) Maitz CA, Tate DJ, Bechtel SM, Lunceford J, Henry CJ, Flesner BK, Collins A, Varterasian M, Tung D, Zhang L, Saha S, and **Bryan JN**. Paired ^{18}F-Fluorodeoxyglucose (^{18}F-FDG), and ^{64}Cu-Copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (^{64}Cu-ATSM) PET scans in dogs with spontaneous tumors and evaluation for hypoxia-directed therapy. *Rad Res*. 2022;197:253-260 doi: 10.1667/RADE-20-00186.1

65) Chambers A, Sidhu D, **Bryan JN**, Torres BT. Bilateral tibial fractures in a cat suspected to be secondary to long term bisphosphonate usage. *J Am Vet Med Assoc*. In press 2020

64) Flesner BK, Wood GW, Gayheart-Walsten P, Sonderegger FL, Henry CJ, Tate DJ, Bechtel SM, Donnelly LL, Johnson GC, Kim DY, Wahaus TA, **Bryan JN**, Reyes N. Autologous Cancer Cell Vaccination, Adoptive T Cell Transfer, and Interleukin-2 Administration Results in Long-Term Survival for Companion Dogs with Osteosarcoma. *J Vet Intern Med*. 2020; 34:205-67. doi: 10.1111/jvim.15852. PMID: 32649801

63) Chu S, Wylie T, Wylie K, Johnson GK, Skidmore Z, Griffith O, **Bryan JN**. A virome sequencing approach to feline oral squamous cell carcinoma to evaluate causative factors. *Vet Microb*. 2020 Jan;240:108491. doi: 10.1016/j.vetmic.2019.108491. PMID: 31902496

62) Dedeaux A, Flesner B, Reinhart J, Langohr I, Husnik R, Geraci S, Taboada J, Rademacher N, Thombs L, **Bryan JN**, Trepanier L, Boudreaux B. Biochemical, Functional, and Histopathologic Characterization of Lomustine-induced Liver Injury in Dogs. *Am J Vet Res*. 2020 epub ahead of print

61) Kumar SR, Gajagowni S, **Bryan JN**, Bodenhausen HM. Molecular targets for tivantinib (ARQ 197) and vasculogenic mimicry in human melanoma cells. *Eur J Pharmacol*. 2019;853:316-324. doi: 10.1016/j.ejphar.2019.04.010

60) Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, **Bryan JN**, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y. NCI Comparative

Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. *Clin Cancer Res*. 2018;24:5830-5840. doi: 10.1158/1078-0432.CCR-18-1498

59) Schaefer EAF, Chu S, Pearce JW, **Bryan JN**, Flesner BK. Papillomavirus DNA not detected in canine lobular orbital adenoma and normal conjunctival tissue. *BMC Vet Res*. 2019;15:226. doi: 10.1186/s12917-019-1971-0

58) Sobolewski J, **Bryan JN**, Duval D, O'Kell D, Tate DJ, Webb T, Moore S. Readability of consent forms in veterinary clinical research. *J Vet Intern Med*. 2019;33:350-355. doi: 10.1111/jvim.15462

57) Selting KA, Bechtel SM, Espinosa J, Henry CJ, Tate D, **Bryan JN**, Rajewski L, Flesner BK, Decedue C, Baltezor M.. Evaluation of intravenous and subcutaneous administration of a novel, excipient-free, nanoparticulate formulation of paclitaxel in dogs with spontaneously-occurring neoplasia. *Vet Comp Oncol*. 2018;16:650-657. doi: 10.1111/vco.12435

56) Menard K, Flesner BK, Glahn A, Boudreaux B, **Bryan JN**. Concurrent 5-fluorouracil and Carboplatin for the Treatment of Canine Carcinomas. *Vet Comp Oncol*. 2018;16:590-595. doi: 10.1111/vco.12426

55) Kumar SR, **Bryan JN**, Eaton A, Robinson K, Gajagowni S. Differential modulation of transcription factors and cytoskeletal proteins in prostate carcinoma cells by a bacterial lactone. *BioMed Res. Int*. 2018:6430504. doi: 10.1155/2018/6430504.

54) Henry CJ, Flesner BK, Bechtel SA, **Bryan JN**, Tate DJ, Selting KA, Lattimer JC, Bryan ME, Grubb L, Hausheer F. Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin. *J Vet Intern Med*. 2018;32:370-376. doi: 10.1111/jvim.14848.

53) DeClue AE, Axiak-Bechtel SM, Zhang Y, Saha S, Zhang L, Tung D, **Bryan JN**. Immune Response to C. novyi-NT Immunotherapy. *Vet Res*. 2018;49:38. doi: 10.1186/s13567-018-0531-0.

52) DeClue AE, Axiak-Bechtel SM, Zhang Y, Saha S, Zhang L, Tung D, Tate DJ, **Bryan JN**. Identification of immunologic and clinical characteristics that predict inflammatory response to C. novyi-NT bacteriolytic immunotherapy. *BMC Vet Res*. 2018;14:119. doi: 10.1186/s12917-018-1424-1.

51) Kumar SR, Taylor KH, **Bryan JN**, Eaton AM. RNA methylation in lymphoid malignancies. *RNA and Disease*. 2017;4:e1563. doi:10.14800/rd.1563

50) **Bryan JN**, Lattimer JC, Jia F, Caldwell CW, Villamil JA, Selting KA, Henry CJ, and Lewis MR. Scintigraphic Imaging of B-cell Lymphoma in Three Dogs Using a Radio-labeled Somatostatin Analogue. *J Vet Sci Med Diagn* 2017:6;1. doi: 10.4172/2325-9590.1000220 Corresponding Author

49) Grobman M, Cohn L, Knapp S, **Bryan JN**, Reinero C. ^{18}F-FDG-PET/CT As Adjunctive Diagnostic Modalities In Canine Fever Of Unknown Origin. *Vet Rad Ultrasound*. 2018; 59:107-115. doi: 10.1111/vru.12562.

48) **Bryan JN**. The current state of clinical application of serum biomarkers for canine lymphoma. *Frontiers in Veterinary Science*. 2016; 3: 87. Doi: 10.3389/fvts.2016.00087 Invited Review

47) Kumar SR, Kim DY, Henry CJ, **Bryan JN**, Robinson KL, Eaton A. Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors. *Vet Comp Oncol*. 2017; 15:1527-1536. doi: 10.1111/vco.12297

46) Tracy CJ, Whiting REH, Pearce JW, Williamson BG, Vansteenkiste DP, Gillespie LE, Castaner LJ, **Bryan JN**, Coates JR, Jensen CA, Katz ML. Intravitreal Implantation of TPP1-Transduced Stem Cells Delays Retinal Degeneration in Canine CLN2 Neuronal Ceroid Lipofuscinosis. *Experimental Eye Research*. 2016; 152:77-87.

45) Memon MA, Shmalberg J, Adair HS, Allweiler S, **Bryan JN**, Cantwell S, Carr E, Chrisman C, Egger CM, Greene S, Haussler KK, Hershey B, Holyoak GR, Johnson M, Le Jeune S, Looney A, McConnico RS, Medina C, Morton AJ, Munsterman A, Nie GJ, Park N, Parsons-Doherty M, Perdrizet JA, Peyton JL, Raditic D, Ramirez HP, Saik J, Robertson S, Sleeper MM, Van Dyke J, Wakshlag J. Integrative Veterinary Medical Education and Consensus Guidelines for an Integrative Veterinary Medicine Curriculum within Veterinary Colleges. *Open Veterinary Journal*. 2016; 6:44-56.

44) Zhang T, Cai S, Groer C, Forrest WC, Yang Q, Mohr E, Douglas J, Axiak-Bechtel SM, Selting KA, Swarz JA, Tate D, Aires D, **Bryan JN**, Forrest ML. Targeted Polymeric ring-chelated cisplatin and its Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines. *J Pharm Sci.* 2016; 105:1891-1900. PMID: 27155765 Co-Senior Author

43) Axiak-Bechtel SM, Maitz C, Selting KA, **Bryan JN**. Preclinical imaging and treatment of cancer – The use of animal models beyond rodents. *Quarterly J Nuc Med Mol Imaging*. 2015; 59:303-16

42) Cai S, Zhang T, Forrest WC, Yang Q, Groer C, Mohr E, Aires DJ, Axiak-Bechtel SM, Flesner BK, Henry CJ, Selting KA, Tate D, Swarz JA, **Bryan JN**, Forrest L. Phase I/II Clinical Trial of HylaPlat for the Treatment of Spontaneous Canine Cancers. *Am J Vet Res*. 2016 ;77:1005-16. Co-Senior Author

41) Kumar SR, **Bryan JN**, Magda E, Amost-Landgraf J, May TJ. Testis specific Y-like 5: Gene expression, methylation, and implications for drug sensitivity in prostate carcinoma. *BMC Cancer*. 2017;17:158. doi: 10.1186/s12885-017-3134-7. 344 accessions as of 3/24/17

40) **Bryan JN**. Fetal microchimerism in cancer protection and promotion: current understanding in dogs and the implications for human health. *Am Assoc Pharm Sci J*. 2015; 17:506-12. Invited Review.

39) Tracy CJ, Sanders N, **Bryan JN**, Jensen CA, Castaner LJ, Kirk MD, Katz ML. Intravitreal Implantation of Genetically Modified Autologous Bone Marrow-Derived Stem Cells for Treating Retinal Disorders. *Advances in Experimental Biology and Medicine*. 2016; 854:571-7.

38) Flesner BK, Kumar SR, **Bryan JN**. 6-Thioguanine and zebularine down-regulate DNMT1 and globally demethylate a canine lymphoma cell line. *BMC Veterinary Research*. 2014; 10:290. 1,423 accessions as of 3/24/17

37) Herrera CL, Kim DY, Kumar SR, **Bryan JN**. Peroxisome proliferator activated receptor γ protein expression is asymmetrically distributed in primary lung tumor and metastatic to lung osteosarcoma samples and does not correlate with gene methylation. *BMC Veterinary Research*. 2015; 11:230. 1,622 accessions as of 8/21/19

36) Robinson KL, Bryan ME, Keeler MR, Hahn AW, **Bryan JN**. Neutering is Highly Associated with Developing Hemangiosarcoma: A Population Study of Dogs (1964-2004). *Can Vet J*. Can Vet J. 2020;61:499-504. PMID: 32355348

35) Arthur EG, Arthur GL, Keeler MR, **Bryan JN**. Open fracture fixation does not increase risk of osteosarcoma in dogs recorded in the Veterinary Medical Database. *Vet Surg*. 2015; 45(1):30-5.

34) Kumar AS, **Bryan JN**, Kumar SR. Bacterial Quorum Sensing Molecule N-3-oxo-Dodecanoyl-L-Homoserine Lactone Causes Direct Cytotoxicity and Reduced Cell Motility in Human Pancreatic Carcinoma Cells. PLoSOne. 2014 Sep 4;9(9):e106480. 9,741 accessions as of 8/21/19

33) Kumar SR, Hansen SA, Axiak-Bechtel SM, **Bryan JN**. The health effects of fetal microchimerism can be modeled in companion dogs. *Chimerism*. 2013;4:139-41. Corresponding author.

32) Axiak-Bechtel SM, Kumar SR, Dank KK, Clarkson NA, Selting KA, **Bryan JN**, Rosol TJ, Espinosa J, Decedue CJ. Antitumor activity of nanoparticulate paclitaxel in PC3 and Ace-1 aggressive prostate cancer cell lines. *Investigational New Drugs*. 2013;31:1609-15.

31) Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, **Bryan JN**, Henry CJ, Boote E, Tate DJ, Bryan ME, Katti KV, Kannan R. Gum Arabic-Coated Radioactive Gold Nanoparticles Cause no Short-term Local or Systemic Toxicity in the Clinically Relevant Canine Model of Prostate Cancer. *Int J Nanomedicine*. 2014;9:5001-11.

30) Axiak-Bechtel SM, Kumar SR, Hansen SA, **Bryan JN**. Y-chromosome DNA is present in the blood of female dogs suggesting the presence of fetal microchimerism. PLoSOne. 2013. 8(7): e68114. doi:10.1371/journal.pone.0068114. Corresponding Author. 4,014 accessions as of 3/24/17

29) Henry CJ, **Bryan JN**. Not lost in translation: How study of diseases in our pets can benefit them and us. *Missouri Medicine*. 2013; 110:144-147.

28) **Bryan JN**, Kumar SK, Jia F, Balkin ER, Lewis MR. Zebularine significantly sensitizes CLL cells to external irradiation and radiopharmaceutical therapy when administered sequentially. *Cell Biology International*. 2014; 38:18-9. Corresponding Author

27) Mattoon JS, **Bryan JN**. The future of imaging in veterinary oncology: what we can learn from human medicine. Vet J. 2013; 197:541-52. Invited Review.

26) Gorman L, **Bryan JN**. Intracavitary and Intralesional Chemotherapy in Dogs and Cats. *Veterinary Medicine.* 2013; 108:114-120. Corresponding Author

25) Krugman L, **Bryan JN**, Mealey KL, Chen-Allen AV. Vincristine-induced central neurotoxicity in a collie homozygous for the ABCB1Δ mutation. *J Sm Anim Pract*. 2012; 53:185-7. Corresponding Author

24) Mohsin, H, Jia F, **Bryan JN**, Sivaguru G, Cutler CS, Ketring AR, Miller WH, Simón J, Frank RK, Theodore LJ, Axworthy DB, Jurisson SS, and Lewis MR. Comparison of Pretargeted and Conventional CC49 Radioimmunotherapy Using ^{149}Pm, ^{166}Ho, and ^{177}Lu. *J Bioconj Chem*. 2011; 22:2444-52.

23) Book AP, Fidel J, Wills T, **Bryan J**, Sellon R, and Mattoon J. Correlation of ultrasound findings, liver and spleen cytology, and prognosis in the clinical staging of high metastatic risk canine mast cell tumors. *Vet Rad Ultrasound*. 2011; 52:548-54.

22) London C, Mathie T, Stingle,N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail D, Hershey B, Ettinger S, Vaughan A, Alvarez F, Hillman L, Kiselow M, Thamm D, Higginbotham ML, Gauthier M, Krick E, Phillips B, LaDue T, Jones P, **Bryan J**, Gill V, Novasad A, Fulton L, Carreras J, McNiell C, Henry C, Gillings Sarah. Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumors. *Vet Comp Oncol*. 2012; 10:194-205.

21) Statham-Ringen KA, Selting KA, Lattimer JC, Henry CJ, Green JA, **Bryan JN**, Jia F, Lewis MR. Evaluation of B-cell leukemia-lymphoma 2-specific radiolabeled peptide-nucleic acid conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma. *Am J Vet Res.* 2012; 73:681-8.

20) Nedrow-Byers J, Jabbes M, Jewett C, Ganguly T, He H, Liu T, Benny P, **Bryan JN**, and Berkman CE. A Phosphoramidate-Based Prostate-Specific Membrane Antigen-Targeted SPECT Agent. *Prostate*. 2012; 72:904-12. Co-senior author.

19) **Bryan JN**, Jia F, Mohsin H, Anderson C, Miller W, Henry CJ, and Lewis MR. Monoclonal Antibodies for Copper-64 PET Dosimetry and Radioimmunotherapy. *Cancer Biology and Therapy*, 2011; 11:1001-7.

18) Liu T, Jabbes M, Nedrow-Byers JR, Wu LY, **Bryan JN**, Berkman CE. Detection of Prostate-Specific Membrane Antigen on HUVECs in Response to Breast Tumor-Conditioned Medium. Int J Oncol. 2011; 38:1349-55. Co-senior author.

17) Vancil JM, Henry CJ, Milner RJ, McCoig AM, Lattimer JC, Villamil JA, McCaw DL, **Bryan JN**. Use of ^{153}Sm-EDTMP for the treatment of dogs with primary tumors of the skull. *J Am Vet Med Assoc*. 2012; 240:1310-5.

16) Tripp, CD, Fidel, J, Anderson, CL, Patrick, M, Pratt, CL, Sellon, RK, **Bryan, JN**. Tolerability of metronomic administration of lomustine in dogs with cancer. *J Vet Intern Med,* 2010; 25: 278-84. Corresponding Author

15) Villamil JA, Henry CJ, Tyler JW, **Bryan JN**, Schultz L, Ellersiek M, Hahn A. Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms. *J Am Vet Med Assoc*. 2011; 239:960-5.

14) Ziegler J, **Bryan JN**, Gabrian K, Memon MA. An integrative approach towards treatment of a downer alpaca. *American Journal of Traditional Chinese Veterinary Medicine*, 2010; 5(2):79-85.

13) Villamil JA, Caldwell CW, Hahn AW, **Bryan JN**, Tyler JW, Henry CJ. Hormonal and gender impact on the epidemiology of canine lymphoma. *Journal of Cancer Epidemiology*. 2009, Article ID 591753, 7 pages

12) **Bryan JN**, Jabbes M, Berent LM, Arthur GL, Taylor KH, Rissetto KC, Henry CJ, Rahmatpanah F, Rankin WV, Villamil JA, Lewis MR, Caldwell CW. Hypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphoma. *BMC Genetics,* 2009; 10(1):73. Corresponding Author. 4,097 accessions as of 3/28/2014.

11) Wise LN, **Bryan JN**, Sellon DC, Hines MT, Ramsay J, Seino KK. A retrospective analysis of renal carcinoma in the horse. *J Vet Intern Med*, 2009; 23:913-8.

10) **Bryan JN**, Bommarito D, Kim DY, Berent LM, Bryan ME, Lattimer JC, Henry CJ, Engelbrecht H, Ketring A, Cutler C. Comparison of systemic toxicity of Lu-177-DOTMP to Sm-153-EDTMP administered intravenously to normal dogs at an equivalent skeletal dose. *J Nucl Med Technol*, 2009;37:45-52. Corresponding Author

9) Tripp CD**, Bryan JN**, Wills TB. Presumptive increase in protein-bound serum calcium in a dog with multiple myeloma. *Veterinary Clinical Pathology*, 2009;38:87-90.

8) **Bryan JN**, Taylor KH, Henry CJ, Selting KA, Rahmatpanah F, Lewis MR, Caldwell CW. DNA Methylation in Cancer: Techniques and Preliminary Evidence of Hypermethylation in a Canine Gene. *Cancer Therapy*, 2008;6:137-148. Corresponding Author

7) **Bryan JN**, Keeler MR, Henry CJ, Bryan ME, Hahn AW, Caldwell CW. A population study of neutering status as a risk factor for canine prostate cancer, *The Prostate*, 2007;67(11):1174-1181. Corresponding Author.

6) McCaw DL, Chan AS, Stegner AL, Mooney B, **Bryan JN**, Turnquist SE, Henry CJ, Alexander H, Alexander S. Proteomics of canine lymphoma identifies potential cancer specific protein markers, *Clin Cancer Res*. 2007;13(8):2496-2503.

5) Suedmeyer WK, **Bryan JN**, Johnson G, Freeman A. Diagnosis and clinical management of multiple chromatophoromas in an eastern yellowbelly racer. *J Zoo Wildl Med*. 2007; 38(1):127-130.

4) **Bryan JN**, Henry C , Turnquist S, Tyler J, Liptak J, Rizzo S, Sfiligoi G, Steinberg H, Smith A, Jackson T. Primary renal neoplasia of dogs: a retrospective review of 82 cases. *J Vet Intern Med*, 2006; 20:1155-1160. Corresponding Author

3) **Bryan JN**, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, Henry CJ, and Lewis MR. Comparative uptakes and biodistributions of internalizing versus non-internalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. *Nucl Med Biol*, 2005; 32(8): 851-858.

2) Henry CJ, Buss MS, Hellström I, Hellström KE, **Bryan JN**, Brewer WG, and Siegall CB. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma. *Clin Cancer Res*, 2005; 11(2 Pt 1):751-55.

1) **Bryan JN**, Lewis MR, Henry CJ, Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru G, Anderson CJ. Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy. *Veterinary and Comparative Oncology* 2004; 2(2):82-90. Corresponding Author
-Nominated for National Phi Zeta Manuscript Award, 2005

Non-refereed Articles:
Bryan JN. *DLC1* as a comparative epigenetic biomarker for radiotherapy of non-Hodgkin's lymphoma, PhD dissertation, June 2007.

Bryan JN. Copper-64-labeled antibodies for the radioimmunotherapy of colon cancer in a mouse model. Masters thesis, December 2004.

Bryan JN, McCaw DL. Photodynamic therapy in companion animals. Advances in Small Animal Medicine and Surgery 2002; 15(12):1-2.

Invited Articles:
Bryan JN. DNA Methylation in Cancer. Veterinary Cancer Society News, Summer 2007.

Book Chapters:
Bryan JN. PET Imaging. Clinical Veterinary Advisor: Dogs and Cats. 4th Edition. Cohn L, Cote E, eds. Elsevier Mosby, St. Louis, MO, 2018, in press.

Bryan JN. Renal Neoplasia. Clinical Veterinary Advisor: Dogs and Cats. 4th Edition. Cohn L, Cote E, eds. Elsevier Mosby, St. Louis, MO, 2018, in press.

Bryan JN. Transitional cell carcinoma. Clinical Veterinary Advisor: Dogs and Cats. 4th Edition. Cohn L, Cote E, eds. Elsevier Mosby, St. Louis, MO, 2018, in press.

Bryan JN. Renal Neoplasia. Clinical Veterinary Advisor: Dogs and Cats. 3rd Edition. Cote E, ed. Elsevier Mosby, St. Louis, MO, 2014: 897-899.

Bryan JN. Transitional cell carcinoma. Clinical Veterinary Advisor: Dogs and Cats. 3rd Edition. Cote E, ed. Elsevier Mosby, St. Louis, MO, 2014: 1015-1016.

Choy K, **Bryan JN**, Lymphoma. The Cat, Clinical Medicine and Management. Susan E. Little ed. Elsevier, St. Louis, MO, 2012: 782-6.

Tripp CD**, Bryan JN.** Equine Melanoma. Clinical Veterinary Advisor: the Horse. Wilson D, Elsevier Saunders, St. Louis, MO, 2012: 355-7.

Bryan JN. Renal Neoplasia. Clinical Veterinary Advisor: Dogs and Cats. 2nd Edition. Cote E, ed. Elsevier Mosby, St. Louis, MO, 2011: 974-6.

Bryan JN. Transitional cell carcinoma. Clinical Veterinary Advisor: Dogs and Cats. 2nd Edition. Cote E, ed. Elsevier Mosby, St. Louis, MO, 2011: 1112-4.

Bryan JN, Henry CJ. Renal Tumors. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010; 286-290.

Bryan JN. Leukemia. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010; 351-354.

Bryan JN. Lymphoma. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010; 343-351.

Bryan JN. Prostate Tumors. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010; 296-298.

DeClue AE, **Bryan JN**. Adrenal and pituitary tumors. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010; 357-362.

DeClue AE, **Bryan JN**. Endocrine Pancreatic tumors. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010; 368-370.

Bryan JN, DeClue AE. Parathyroid tumors. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010; 366-368.

Bryan JN, DeClue AE. Thyroid tumors. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010; 362-366.

McCaw DW, **Bryan JN**. Photodynamic Therapy. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010: 163-166.

Lattimer J**, Bryan JN**. Radioisotopes in Cancer Therapy. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010; 151-153.

Tripp CD, **Bryan JN**. Multiple Myeloma. Small Animal Clinical Oncology. Henry CJ, Higginbotham ML, ed. Saunders Elsevier, Maryland Heights, MO, 2010; 354-356.

Section Editor
Oncology. The Cat, Clinical Medicine and Management, 2nd ed. Susan E. Little ed. Elsevier, St. Louis, MO, 2020: XXX-XXX.

Oncology. The Cat, Clinical Medicine and Management. Susan E. Little ed. Elsevier, St. Louis, MO, 2012: 768-806.

Oncology, Clinical Veterinary Advisor: the Horse. Wilson D, Elsevier Saunders, St. Louis, MO, 2012.

Proceedings:
Bryan JN, Tumor Microenvironment. Veterinary Technician Cancer Society Annual Meeting. Louisville, KY. 2018

Bryan JN. Imaging in Oncology. Veterinary Technician Cancer Society Annual Meeting. Orlando, FL. 2016

Bryan JN. Managing Hemangiosarcoma. Southwest Veterinary Symposium. Ft. Worth, TX 2015

Bryan JN. Lymphoma Rescue Chemotherapy. Southwest Veterinary Symposium. Ft. Worth, TX 2015

Bryan JN. Urinary Tract Tumors. Southwest Veterinary Symposium. Ft. Worth, TX 2015

Bryan JN. What is New for Lymphoma? Southwest Veterinary Symposium. Ft. Worth, TX 2015

Bryan JN. New Developments in Oncology That You Must Know About! Southwest Veterinary Symposium. Ft. Worth, TX 2015

Bryan JN. That lump is too big! How can I manage that? Southwest Veterinary Symposium. Ft. Worth, TX 2015

Bryan JN. Managing Hemangiosarcoma. 8th Keystone Veterinary Conference. Hershey, PA 2014

Bryan JN. Urinary Tract Tumors. 8th Keystone Veterinary Conference. Hershey, PA 2014

Bryan JN. What is New for Lymphoma? 8th Keystone Veterinary Conference. Hershey, PA 2014

Bryan JN. Practical application of novel biomarkers. World Congress on Controversies, Debates & Consensus in Veterinary Medicine (CoVet). Prague, Czech Republic - October 23-25, 2014

Bryan JN. Metronomic therapy: Hype or hope?. World Congress on Controversies, Debates & Consensus in Veterinary Medicine (CoVet). Prague, Czech Republic - October 23-25, 2014

Bryan JN. New Developments in Oncology That You Must Know About! 8th Keystone Veterinary Conference. Hershey, PA 2014

Bryan JN. That lump is too big! How can I manage that? 8th Keystone Veterinary Conference. Hershey, PA 2014

Bryan JN. Special stains are recommended, but what are they? 8th Keystone Veterinary Conference. Hershey, PA 2014

Bryan JN. Clinical Trials: Planning for Success. ACVIM Forum 2014

Bryan JN. Epigenetic Contributions to Lung Disease. 30th Annual Veterinary Comparative Respiratory Society Symposium October 2012.

Bryan JN. Urinary Tract Tumors. AVMA Convention 2012

Bryan JN. Managing Hemangiosarcoma. AVMA Convention 2012

Bryan JN. What is New for Lymphoma? AVMA Convention 2012

Bryan JN. DNA Methylation: Understanding Dogs to Understand Humans. ACVIM Forum 2012

Bryan JN. Lymphoma Chemotherapy Decision Making. Wild West Veterinary Conference 2010

Bryan JN. Hemangiosarcoma. Wild West Veterinary Conference 2010

Bryan JN. Urinary Bladder Transitional Cell Carcinoma. Wild West Veterinary Conference 2010

Bryan JN. Anti-Angiogenesis. Wild West Veterinary Conference 2010

Bryan JN. Unusual Lymphomas. Wild West Veterinary Conference 2010

Bryan JN. What is new in chemotherapy for canine lymphoma?

Bryan JN. New developments in oncology that you must know about! AVMA Convention 2010

Bryan JN. That lump is too big! How can I manage that? AVMA Convention 2010

Bryan JN. Special stains are recommended, but what are they? AVMA Convention 2010

Bryan JN. Bladder Cancer—Diagnosis and Treatment. AVMA Convention 2009

Bryan JN. Clinical Decision Making in Canine Hemangiosarcoma. AVMA Convention 2009

Bryan JN. Anti-angiogenic Therapy of Companion Animal Cancers. AVMA Convention 2009

Bryan JN. Atypical Presentations of Lymphoma and Treatment Options. AVMA Convention 2009

Bryan JN. Neoplasia in Rabbits: Diagnosis and Staging. Western Veterinary Conference 2009.

Bryan JN. Neoplasia in Rabbits: Therapy. Western Veterinary Conference 2009.

Bryan JN. The Rabbit Won't Eat: What Next? Western Veterinary Conference 2009.

Bryan JN. E. cuniculi: Past, Present, and Future. Western Veterinary Conference 2009.

Bryan JN. Clinical Applications of Molecular Imaging of Cancer. ACVIM Forum 2008

Bryan JN. Rescue Chemotherapy for Canine Lymphoma: What Next? ACVIM Forum 2008

Bryan JN. Tumor Staging: Wish I Didn't Know Now What I Didn't Know Then. WSU Annual Conference 2008

Bryan JN. Literature-Based Approach to Chemotherapy of Lymphoma in Cats and Dogs. WSU Annual Conference 2008

Bryan JN. Oncologic Emergencies. WSU Annual Conference 2008

Bryan JN. Management of Hemangiosarcoma and Mast Cell Tumors. WSU Annual Conference 2008

Bryan JN. Literature-Based Approach to Chemotherapy of Lymphoma in Cats and Dogs. 2007 AVMA Convention

Bryan JN. When Chemotherapy Fails: Lymphoma Rescue. 2007 AVMA Convention

Bryan JN. Tumor Staging: Wish I Didn't Know Now What I Didn't Know Then. 2007 AVMA Convention

Bryan JN. Epigenomics: Same Code Different Function. ACVIM Forum 2007

Maxwell LK, **Bryan JN**. Cytotoxic chemotherapy, what is the evidence that benefit outweighs risk? ACVIM Forum 2007

Abstracts:

145) Tripp C, Bryan JN, Olson M, Murray B. Enhanced anti-tumor efficacy of Electrochemotherapy combined with marginal surgery in dogs with Soft Tissue Sarcomas & Mast Cell Tumors. American College of Veterinary Surgeons Surgery Summit, October 23-25, 2025, Seattle WA.

144) Crist S, **Bryan JN**, An H, Maitz CA. O6-methylguanine-DNA-methyltransferase (MGMT) gene methylation status in canine intracranial glioma tissue samples. Annual Conference Proceedings of the Veterinary Cancer Society, September 25-27, 2025, Salt Lake City, UT. Resident Award Winner

143) Yang V, Talbott J, **Bryan JN**, Valentijn A, Mosley R, Baumgardner R, Lunceford J, Lewis M. Novel application of $^{64}CuCl_2$ for PET imaging of cats with mammary carcinoma. Annual Conference Proceedings of the Veterinary Cancer Society, September 25-27, 2025, Salt Lake City, UT.

142) **Bryan JN**, Wahaus, T, Wright Z, Shor S, Back A, Shah T, Reyes N. One-dose carboplatin followed by vaccine-enhanced adoptive cell therapy (ECI®) improves outcomes compared to four-dose carboplatin in dogs with osteosarcoma. Annual Conference Proceedings of the Veterinary Cancer Society, September 25-27, 2025, Salt Lake City, UT.

141) Mosley R, Sax A, Garrett C, Mason N, Fuhrer A, Iwaki Y, Maitz C, Marquardt T, Talbott J, Nolan M, **Bryan JN**. Evaluating the safety and preliminary efficacy of combining palliative radiation with anti-CTLA4 immunotherapy in dogs with stage III, IV oral melanoma. Annual Conference Proceedings of the Veterinary Cancer Society, September 25-27, 2025, Salt Lake City, UT.

140) Yannai L, Talbott J, Chu S, Garrett C, Combs D, Barbour A, Valentijn A, Mosley R, Iwaki Y, Marquardt T, Rippy S, Bruyette D, **Bryan JN**. Evaluation of verdinexor (Laverdia-CA1) for treatment of naïve canine cutaneous epitheliotropic lymphoma. Annual Conference Proceedings of the Veterinary Cancer Society, September 25-27, 2025, Salt Lake City, UT.

139) **Bryan JN**, Wahaus T, Wright ZSM, Shor S, Back AR, Bergman P, Wood G, Carter W, Skikne B, Shah TD, Reyes N. Abstract C065: Vaccine-enhanced adoptive cell therapy combined with one dose of platinum-based chemotherapy improves outcomes compared to standard of care four-dose carboplatin in dogs with osteosarcoma. Cancer Epidemiol Biomarkers Prev (2025) 34 (9_Supplement): C065.

138) **Bryan JN**, Wahaus T, Wright ZSM, Shor S, Back AR, Bergman P, Wood G, Carter W, Skikne B, Shah TD, Reyes N. Adoptive cell therapy with chemotherapy improves canine osteosarcoma outcomes compared to standard of care chemotherapy. ACVIM Forum, Louisville, KY June 19-21, 2025.

137) Barbour A, Donnelly L, Hancock T, Golzy M, Garrett C, Miget S, Talbott J, **Bryan JN**. Concordance between examination, gross cytologic appearance, and cytology for diagnosis of cutaneous and subcutaneous lipomas in dogs. Annual Conference Proceedings of the Veterinary Cancer Society, October 17-19, 2024, Orlando, FL.

136) **Bryan JN**, Reyes N, Wahaus T, Wang G, Hendricks W, Flesner BK, Henry CJ. Gene sequencing identifies potential biomarkers of early failure and death in dogs with osteosarcoma treated with amputation and vaccine-enhanced activated T cell therapy. Annual Conference Proceedings of the Veterinary Cancer Society, October 17-19, 2024, Orlando, FL.

135) Sawyer K, **Bryan JN**, Iwaki Y, Maitz CA, Marquardt T, Talbott JL, Olson K, Tran-Hoang C. A retrospective evaluation of a single institution's use of toceranib for non-mast cell neoplasia. Annual Conference Proceedings of the Veterinary Cancer Society, October 17-19, 2024, Orlando, FL.

134) Innokenteva Y, **Bryan JN**, Li G, Rodney A, Culp WTN, Dickinson P, Koutoulas A, Megquier K, An H, Kramer S, Rice E, Mitchem J, Warren WC. New molecular insight into the tumor microenvironment of canine hepatocellular carcinoma. ICCFG, Helsinki, Finland.

133) Olson KO, **Bryan JN**, Garret CJ, Simenson A. Lymphocyte-monocyte ratio to predict disease status and outcome in dogs with osteosarcoma. Annual Conference Proceedings of the Veterinary Cancer Society, October 12-14, 2023, Reno NV.

132) **Bryan JN**, Garret CJ, Lunceford J, Kil KE, Schueller M, Miget S, Carroll V, Sproul T, Suhy D, Anderson CJ. Translating a cancer-agnostic screening PET agent system in dogs for early detection of cancer in humans. Annual Conference Proceedings of the Veterinary Cancer Society, October 12-14, 2023, Reno NV.

131) Joshi KV. Sirpu N, Shanmugam M, Poonooru RR, Subramanyam P, Garrett C, Schlink S, Gerb S, Porter J, Yariswamy M, Nagaraj S, Kim DY, Kunin J, Hoffman T, Telugu B, **Bryan JN**, Kaifi J, Rachagani S. Lung Tumor Induction in a Transgenic Oncopig Model. 19th Annual Academic Surgical Congress, Feb 6-8, 2024, Washington DC.

130) Jing W, Shinglot H, Ng JCK, Zhang A, Al-Marayaty R, Wu J, **Bryan JN**, Pollack SM. Novel IL-12 gene delivery vehicles for transformation of spontaneous canine soft-tissue sarcomas. Society for Immunotherapy of Cancer, November 1 - 5, 2023 in San Diego, CA.

129) **Bryan JN**, Maitz CA, Hennkens HM, Hoerres R, Lunceford J, Donnelly LL, Cowan C, Hovis K, Przydrozny A, Zeglis BM. In vivo click chemistry can target radioactivity to tumor lesions. Annual Conference Proceedings of the Veterinary Cancer Society, October 13-15, 2022, Norfolk, VA.

128) Maitz CA, **Bryan JN**, Donnelly LL, Ashworth HL, Wyatt WL, Andruska N, Kavanaugh J, Garrett C, Miget S, Spraker M. Lattice SBRT for palliation of large soft tissue sarcomas in dogs. Radiation Research Society Annual Meeting, October 16-19, Kona, HI.

127) Nguy S, Rindt H, **Bryan JN**, Reinero CN. Assessing changes in myeloid derived suppressor cells in canine melanoma patients treated with immunotherapy. Veterinary Research Scholars Symposium, 2021.

126) Noall LG, **Bryan JN**, Chu S. BRAF mutations in feline tumors. Veterinary Research Scholars Symposium, 2021.

125) Fu Y, Yu J, Liatsou I, Josefsson A, Du Y, **Bryan JN**, Kraitchman DL, and Sgouros G. Abstract 1395: Humanized GD2 antibody for targeted radiopharmaceutical therapy of human and canine osteosarcoma. Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA.

124) Skidmore ZL, Rindt H, Chu S, Fisk B, Fronick C, Fulton R, Zhou M, Bivens NJ, Reinero CN, Griffith M, **Bryan JN**, Griffith OL. Single Cell T Cell Receptor Repertoire Profiling for Dogs. Annual Conference Proceedings of the Veterinary Cancer Society, October 14-16, 2021, Boise, ID.

123) Donnelly LL, Couto J, Lemoine L, Erger C, Rindt H, Flesner BK, McCleary-Wheeler A, **Bryan JN**, Ericsson A. Prospective evaluation of the fecal microbiome in dogs with lymphoma treated with CHOP chemotherapy. Annual Conference Proceedings of the Veterinary Cancer Society, October 14-16, 2021, Boise, ID.

122) Couto J, Donnelly LL, Kermendy K, Erger C, Rindt H, Flesner BK, McCleary-Wheeler A, **Bryan JN**, Ericsson A. Prospective evaluation of the fecal microbiome in dogs with cancer receiving doxorubicin chemotherapy. Annual Conference Proceedings of the Veterinary Cancer Society, October 14-16, 2021, Boise, ID.

121) Flesner BK, Rogic A, Maitz CA, Rindt H, Norquest CJ, Ashworth HL, Donnelly LL, **Bryan JN**, McCleary-Wheeler AL. Zoledronic acid and coarsely fractionated external beam radiotherapy: effective limb-sparing treatment for canine osteosarcoma. Annual Conference Proceedings of the Veterinary Cancer Society, October 14-16, 2021, Boise, ID.

120) Henry C, Abraham R, Liu D, Gordon A, **Bryan JN**, Kappadath CS, Syme A, Mawko G, Strugari M, Brewer K. CT-based Dosimetry in Yttrium-90 Radioembolization Performed in a Rabbit Liver Model. Global Embolization Symposium and Technologies. July 31, 2021

119) Reising A, Donnelly LL, Flesner BK, Maitz CA, **Bryan JN**. Solitary osseous plasmacytomas in dogs: a retrospective review of 13 cases. Oral presentation – Virtual Veterinary Cancer Society 2020

118) **Bryan JN**, Lunceford J, Bai B. Evaluation of PET Image Quality Using Non-Conventional Isotopes. Annual Meeting of the Society for Nuclear Medicine and Molecular Imaging. June 13-16, 2020, New Orleans, LA.

117) Flesner BK, Wood GW, Sonderegger FL, Tate DJ, Donnelly LL, Wahaus TA, Reyes N, **Bryan JN**. Autologous Activated T Cell Therapy for Osteosarcoma of Companion Dogs. Society for Immunotherapy of Cancer, November 6-10, 2019, National Harbor, MD.

116) Reich SN, Kim DY, Wiggen K, Liu P, **Bryan JN**. HER2 protein expression in canine tissues and relevance as an immunotherapeutic target in canine osteosarcoma. Health Sciences Research Day, University of Missouri, November 21, 2019, Columbia, MO.

115) Flesner BK, Torres B, Hutcheson D, Maitz CA, Tate D, Donnelly LL, McCleary-Wheeler A, Rindt H, Lunceford J, **Bryan JN**. Multi-modal Pain Assessment of Client-owned Dogs with Primary Bone Tumors. KCMD Consortium: 4th Annual Musculoskeletal and Neuromuscular Diseases Symposium, Kansas City, MO.

114) Maitz C, Fisher D, Flesner BK, Donnelly L, McCleary-Wheeler A, Lunceford J, Riley B, Tate D, **Bryan JN**. As-delivered dosimetry, tolerability, and outcome for intralesional delivery of Isopet ^{90}Y-hydrogel in dogs with soft tissue sarcoma. Annual Conference Proceedings of the Veterinary Cancer Society, October 17-19, 2019, Houston, TX.

113) **Bryan JN.** Canine lymphoma: are we doing enough? Annual Conference Proceedings of the Veterinary Cancer Society, October 17-19, 2019, Houston, TX.

112) Chu S, Wylie TN, Wylie KM, Johnson GC, Griffith OL, **Bryan JN**. A virome sequencing approach to feline oral squamous cell carcinoma to evaluate causative factors. Annual Conference Proceedings of the Veterinary Cancer Society, October 17-19, 2019, Houston, TX.

111) Reich SN, Kim DY, Wiggen K, Liu P, **Bryan JN**. HER2 protein expression in canine tissues and relevance as an immunotherapeutic target in canine osteosarcoma. Annual Conference Proceedings of the Veterinary Cancer Society, October 17-19, 2019, Houston, TX.

110) Flesner B, Torres B, Hutcheson D, Maitz CA, Tate DJ, Donnelly L, McCleary-Wheeler A, Rindt H, Lunceford J, **Bryan JN**. Multi-modal Pain Assessment of Dogs with Primary Bone Tumors. Annual Conference Proceedings of the Veterinary Cancer Society, October 17-19, 2019, Houston, TX.

109) Martens E, Donnelly L, **Bryan JN**, Flesner BK, McCleary-Wheeler A, Chu S, Norquest C, Reich S, Couto J. Efficacy and Tolerability of Vinblastine Substitution in LOPP for Refractory Canine Lymphoma. Annual Conference Proceedings of the Veterinary Cancer Society, October 17-19, 2019, Houston, TX.

108) Reich SN, **Bryan JN**. HER2 antibody validation in dogs and expression pattern in canine osteosarcoma cell lines and tissues. University of Missouri Life Sciences Week, April 2019, Columbia MO.

107) Harrison NJ, Fleer MK, Kumar SR, **Bryan JN**, and Flesner BK. The in vitro Effects of Demethylating Agents Decitabine and 6-Thioguanine in Canine Osteosarcoma. AALAS National Meeting, October 28-November 1, 2018, Baltimore, MD.

106) Flesner BK, Tate DJ, Bechtel SA, Donnelly LL, **Bryan JN**. Autologous Activated T cell Therapy for Canine Osteosarcoma. Annual Conference Proceedings of the Veterinary Cancer Society, October 18-20, 2018, Louisville, KY.

105) **Bryan JN**, Evenski A, Johnson G, Tate D, Lunceford J, Honig R, Armstrong K, Flesner BK, Luther J, Axiak-Bechtel SM, Selting KA, Rippy SB, Chu S, Robinson K, Blackwell B. F-18-FDG PET Scan Predicts Regions of Highest Mitotic Activity in High Grade Soft-Tissue Sarcomas and Liposarcomas. Annual Conference Proceedings of the Veterinary Cancer Society, October 18-20, 2018, Louisville, KY. Selected as a State of the Art presentation.

104) Flesner BK, Tate DJ, Bechtel SA, Donnelly LL, **Bryan JN**. Autologous Activated T cell Therapy for Osteosarcoma of Companion Dogs. Paws for a Cure Research Symposium, November 12-13, 2018 in Boston, MA.

103) Maitz CA, Tate D, Axiak-Bechtel SM, Lunceford J, Henry CJ, Selting KA, Flesner BK, Collins A, Varterasian M, Tung D, Zhang L, Saha S, and **Bryan JN**. Evaluation of co-registered Computed Tomography, ^{18}F-Fluorodeoxyglucose (FDG), and ^{64}Cu-Copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (Cu-ATSM) in dogs with spontaneous soft tissue sarcomas. Canine Health Foundation Conference, August 2017, St. Louis, MO.

102) Fray L, Hansen S, Kumar SR, Rindt H, Fleer M, **Bryan JN**. Detecting fetal microchimerism in Equids. National Veterinary Scholars Symposium. August 2017.

101) Kumar SR, Henry CJ, **Bryan JN**, and Petrylak D. Leveraging BET inhibitor ARV-825 for targeting human and dog transitional cell carcinoma – a one health one medicine approach. Annual Conference Proceedings of the Veterinary Cancer Society, October 26-28, 2017, Portland, OR.

100) Larue M, Flesner BK, Shiomitsu K, Burke B, Maitz C, **Bryan JN**. Treatment of Canine Apocrine Gland Anal Sac Adenocarcinoma with Adjuvant Radiation Therapy: 71 cases. Annual Conference Proceedings of the Veterinary Cancer Society, October 26-28, 2017, Portland, OR.

99) Dedeaux A, Flesner BK, Langohr IM, Rademacher N, Reinhart JM, Trepanier LA, Bryan ME, **Bryan JN**, Husnik R, Taboada J, Boudreaux BB. CCNU-induced Hepatotoxicity in Healthy Dogs. Annual Conference Proceedings of the Veterinary Cancer Society, October 26-28, 2017, Portland, OR.

98) Shah TD, Bryan JN, Lightfoot T. Multi-center evaluation of the canine lymphoma blood test as a predictor of chemotherapy failures. Annual Conference Proceedings of the Veterinary Cancer Society, October 26-28, 2017, Portland, OR.

97) Chu, S, Skidmore Z, Kunisaki J, Walker J, Griffith M, Griffith O, **Bryan JN**. Piecing back together the chaotic genomic landscape of canine osteosarcoma with current sequencing technologies and bioinformatic approaches. Annual Conference Proceedings of the Veterinary Cancer Society, October 26-28, 2017, Portland, OR. Resident Award Winner

96) Lu D, Pang P-C, Lafrenz D, Haslam SM, **Bryan JN**, Clark GF, Dell A. Human and canine melanoma cells express glycoconjugates that have previously been implicated in the suppression of innate and adaptive immune responses. Annual Conference Proceedings of the Veterinary Cancer Society, October 26-28, 2017, Portland, OR.

95) **Bryan JN**, Lafrenz D, Tate DJ, Rindt H, Flesner BK, Bechtel SM, Reinero C, Henry CJ, Luther J, Menard K, Chu S, Rippy S, Robinson K, Selting KA, Haslam SM, Dell A, Clark GF. Manipulating cellular glycosylation to enhance therapeutic autologous vaccine efficacy for oral melanoma in dogs.

Annual Conference Proceedings of the Veterinary Cancer Society, October 26-28, 2017, Portland, OR.

94) Chu S, **Bryan JN**, Avery A, Wilson-Robles H. Diffuse Large B Cell Lymphoma (DLBCL) of Golden Retrievers Has a Unique DNA Methylation Signature That Yields Biomarkers of Disease. Canine Health Foundation Conference, August 2017, St. Louis, MO.

93) Harrison NJ, Hansen SA, Maitz CA, **Bryan JN**, Flesner BK. A 3-D Printed Apparatus for Small Animal Imaging. University of Missouri Life Sciences Day, April 2017.

92) Bechtel SM, Marks DL, Zhu X, Selting KA, Flesner BK, Tate DJ, Angle BM, Henry CJ, **Bryan JN**, Gruber KA, Scholten DG, Callahan MF. Canine model - Safety and efficacy of TCMCB07, a novel melanocortin-4 receptor antagonist. *J. Cachexia Sarcopenia Muscle*, 2017; 8: 147. DOI: 10.1002/jcsm.12186

91) **Bryan JN**, Curiel D, Dmitriev I, Kashentseva E, Rindt H, Reinero C, Henry CJ. Viroimmunotherapy for malignant melanoma in the companion dog model. *Clin Trans Med* 2016;5:Suppl 1.

90) Kumar SR, Henry CJ, **Bryan JN**, and Petrylak DP. Leveraging BET inhibitor ARV-825 for targeting human and dog transitional cell carcinoma – a one health one medicine approach. 'Discovery on Target" Cambridge Health Institute Conference, September 2016, Boston, MA.

89) Flesner BK, Tate DJ, Bechtel SM, **Bryan JN**, Selting KA, Henry CJ. Tavocept Enables a Shortened Diuresis Protocol for Dogs with Appendicular Osteosarcoma Receiving Cisplatin. 35th Annual Conference Proceedings of the Veterinary Cancer Society, October 20-22, 2016, Orlando FL.

88) Chu S, **Bryan JN**, Avery A, Wilson-Robles H. The epigenetic signature of diffuse large b cell lymphoma (DLBCL) in golden retrievers. 35th Annual Conference Proceedings of the Veterinary Cancer Society, October 20-22, 2016, Orlando FL.

87) Selting K, Simon J, Lattimer J, Ketring A, Axiak-Bechtel S, Frank K, Wendt RE, **Bryan JN**, Tate D, Maitz C, Lunceford J, Donnelly L, Keegan K. Evaluation of CycloSam (Sm-153-DOTMP) bone seeking radiopharmaceutical in dogs with spontaneous appendicular osteosarcoma. 35th Annual Conference Proceedings of the Veterinary Cancer Society, October 20-22, 2016, Orlando FL.

86) **Bryan JN**, Chu S, Avery A, Wilson-Robles H. Whole-methylome sequencing reveals aberrant DNA methylation in critical cell control genes in canine diffuse large b cell lymphoma (DLBCL). 35th Annual Conference Proceedings of the Veterinary Cancer Society, October 20-22, 2016, Orlando FL.

85) Maitz CA, Kumar SR, **Bryan JN**. Chemosensitization for canine transitional cell carcinoma using low-dose radiation. Radiation Research Society Annual International Meeting. October 16-19, 2016, Waikoloa Village, HI.

84) Chu S, Avery A, Wilson-Robles H, **Bryan JN**. The epigenetic signature of diffuse large b cell lymphoma (DLBCL) in golden retrievers. MU Informatics Symposium 2016.

83) Whiting REH, Tracy CJ, Pearce JW, Gillespie LE, Williamson BG, Vansteenkiste DP, Coates JR, **Bryan JN**, Katz ML. Retinal function and structure are preserved in a canine model of CLN2 disease after intravitreal implantation of stem cells genetically modified to over-produce TPP1 enzyme. The Association for Research in Vision and Ophthalmology annual meeting. May 1-5, 2016, Seattle, WA.

82) Henry CJ, Kumar SR, May TJ, **Bryan JN**, Eaton AM, Petrylak DP. Characterization of decorin and programmed death ligand-1 expression supports the role of canine urothelial transitional cell carcinoma as a model of human bladder cancer. 34th Annual Conference Proceedings of the Veterinary Cancer Society, October 15-17, 2015, Tyson VA.

81) **Bryan JN**, Chu S, Hansen S, Kumar SR, Mautone J. Fetal microchimerism is rare in nulliparous and lymphoma-affected Golden Retrievers. 34th Annual Conference Proceedings of the Veterinary Cancer Society, October 15-17, 2015, Tyson VA.

80) Kumar SR, May TJ, Henry CJ, **Bryan JN**, Eaton AM. Evaluation of programmed death ligand gene and protein expression in canine hematologic malignant cells. 34th Annual Conference Proceedings of the Veterinary Cancer Society, October 15-17, 2015, Tyson VA.

79) **Bryan JN**, Tate D, Bechtel SM, Choy K, Donnelly L, Fitzpatrick K, Flesner BK, Fowler B, Gallis B, Henry CJ, Herrera C, Jabbes M, Selting KA, Sasaki T. Randomized, blinded, placebo-controlled trial of artesunate with doxorubicin for B cell lymphoma of dogs. ACVIM Forum, June 4-7, 2014, Nashville, TN.

78) Flesner BK, Kumar SR, **Bryan JN**. Demethylating agents cause global demethylation and downregulation of DNMT-1 in a canine lymphoma cell line. 33rd Annual Conference Proceedings of the Veterinary Cancer Society, Minneapolis, MN 2013.

77) Tate D, Maitz C, Axiak-Bechtel SA, Avenell J, Lunceford J, Henry CJ, Selting KA, Flesner B, Donnelly L, Fowler B, Herrera C, Glahn A, Collins A, Varterasian M, Tung D, Roix J, Zhang L, Saha S, **Bryan JN**. Cu-64-ATSM PET scanning predicts degree and location of tumor hypoxia in dogs for hypoxia-directed therapy. 33rd Annual Conference Proceedings of the Veterinary Cancer Society, Minneapolis, MN 2013.

76) Herrera C, Tate D, Maitz C, Axiak-Bechtel SA, Avenell J, Lunceford J, Henry CJ, Selting KA, Flesner B, Donnelly L, Fowler B, Glahn A, Collins A, Varterasian M, Tung D, Roix J, Zhang L, Saha S, **Bryan JN**. Hypermetabolic tumor volume can be calculated from PET/CT imaging for response definition. 33rd Annual Conference Proceedings of the Veterinary Cancer Society, Minneapolis, MN 2013.

75) Selting KA, Bechtel SM, Decedue C, Henry CJ, **Bryan JN**. Pharmacokinetics of Crititax®, a novel nanoparticle formulation of paclitaxel, in tumor-bearing dogs. 33rd Annual Conference Proceedings of the Veterinary Cancer Society, Minneapolis, MN 2013.

74) Flesner BK, Kumar SR, **Bryan JN**. 6-Thioguanine Demethylates DNA in a Canine Lymphoma Cell Line and Inhibits Growth. Phi Zeta Research Day, University of Missouri, May 2013.

73) Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, **Bryan JN**, Henry CJ, Tate DJ, Bryan ME, Katti KV, Kannan R. Phase 1 Trial of Radioactive Gold Nanoparticle

Therapy in Dogs with Naturally Occurring Prostate Cancer. Mizzou Advantage Day, University of Missouri, April 30, 2013.

72) Kumar S, **Bryan JN**. Testis-Specific Y-like gene, a possible marker for aggressive biology, is expressed in canine prostate carcinoma cells. Mizzou Advantage Day, University of Missouri, April 30, 2013.

71) Hansen S, Kumar S, Axiak-Bechtel SM, **Bryan JN**. Canine Fetal Microchimerism. Mizzou Advantage Day, University of Missouri, April 30, 2013.

70) **Bryan JN**, Herrera C, Kumar S, Katti KV, Kannan R, Upendran A, Cutler C, Davis W, Bechtel S, Lattimer J, Tate DJ, Dong X, Joshi T. Of Dogs and Men: the Roots of Prostate Cancer. Mizzou Advantage Day, University of Missouri, April 30, 2013.

69) **Bryan JN**, D Tate, S Cai, L Forrest, KA Selting, B Flesner, SM Axiak-Bechtel, CJ Henry, M Cohen. Phase I/II Evaluation of Cisplatin Hyaluronan Nanoparticles in Tumor-Bearing Dogs. Mizzou Advantage Day, University of Missouri, April 30, 2013.

68) **Bryan JN**, D Tate, A Glahn, B Fowler, B Flesner, K Fitzpatrick, C Herrera, L Donnelly, SM Axiak-Bechtel, KA Selting, CJ Henry. Comparative Veterinary Clinical Trial of Artesunate or Placebo with Doxorubicin for Lymphoma in Dogs as Preclinical Evidence of Efficacy. Mizzou Advantage Day, University of Missouri, April 30, 2013.

67) Forrest LM, Cai S, Aires D, **Bryan JN**, Worley D. Formulation development and pharmacokinetics of subcutaneously injected HylaPlatTM in spontaneous canine cancers. HA 2013, Oklahoma City, OK, June 2-7.

66) Hansen SA, Kumar SR, Bechtel SM, **Bryan JN**. Canine fetal microchimerism. Phi Zeta Research Day, University of Missouri, May 3, 2013.

65) Hansen SA, Kumar SR, Bechtel SM, **Bryan JN**. Canine fetal microchimerism. Missouri Life Sciences Week, April 15-19, 2013.

64) SR Kumar, **Bryan JN**. EGCG decreases DNA methylation and sensitizes canine prostate cancer cells to mitoxantrone cytotoxicity. 32nd Annual Conference Proceedings of the Veterinary Cancer Society, Las Vegas, NV 2012.

63) Robinson KL, **Bryan JN**, Keeler M, Hahn A. Neutering is Highly Associated with Developing Canine Hemangiosarcoma: A Population Study (1964-2004). 32nd Annual Conference Proceedings of the Veterinary Cancer Society, Las Vegas, NV 2012.

62) Herrera C, Kumar SR, **Bryan JN**. Identifying DNA Methylation Marks as Potential Biomarkers for Canine Metastatic Osteosarcoma and Primary Lung Cancer. 32nd Annual Conference Proceedings of the Veterinary Cancer Society, Las Vegas, NV 2012.

61) Axiak SM, Lattimer J, Selting K, Henry CJ, **Bryan JN**, Cutler C, Katti K, Upendran A, Kannan R. Phase I Clinical Trial of Intratumorally Administered Radioactive Gold Nanoparticles in Canine Prostatic Carcinoma. World Veterinary Cancer Meeting, Paris, France, March 2012.

60) Henry CJ, Selting KA, Axiak, SM, **Bryan JN**, Tate DJ, Hausheer F. The novel chemoprotectant drug, Tavocept^{TM}, facilitates a shortened cisplatin infusion for treatment of cancer-bearing dogs. World Veterinary Cancer Meeting, Paris, France, March 2012.

59) Selting KA, Axiak SM, **Bryan JN**, Decedue C, Henry CJ. Phase I/II Clinical Trial of CTI52010 in Tumor-Bearing Dogs. World Veterinary Cancer Meeting, Paris, France, March 2012.

58) **Bryan JN,** Jabbes M, Settles M. Aberrent DNA methylation is non-random in canine lymphoma with affected gene families similar to human lymphoma. 31st Annual Conference Proceedings of the Veterinary Cancer Society, Albuquerque, NM 2011.

57) **Bryan JN**, Caldwell CW, Arthur GL, Jabbes M. Use of spontaneously arising canine lymphoma as a preclinical model of DNA methylation derangements for drug target identification. *Curr Med Chem.* 2011;18:15s. Impact Factor 4.708.

56) Pratt CL, Sellon RK, **Bryan JN**, Fidel J. Arsenic Trioxide Sensitizes Glocorticoid-Resistant Canine Lymphoma Cells to Apoptotic Death. 2011 ACVIM Forum, Denver, CO.

55) **Bryan JN**, Jabbes M, Settles ML. Gene promoter and CpG island DNA methylation and gene expression are altered in canine non-Hodgkin lymphoma. American Association of Cancer Research. Orlando, FL.

54) Anderson C, Fidel J, Sellon R, **Bryan JN**, Tripp C. Comparison of abdominal ultrasound and magnetic resonance imaging for detection of abdominal lymphadenopathy in dogs with metastatic anal sac gland adenocarcinoma. 30th Annual Conference Proceedings of the Veterinary Cancer Society, San Diego, CA, 2010.

53) Herrera CL, Tripp CD, Henry CJ, Selting KA, **Bryan JN**. Resting TSH has no effect on ^{99m}TcO4 uptake in canine thyroid carcinoma. 30th Annual Conference Proceedings of the Veterinary Cancer Society, San Diego, CA, 2010.

52) **Bryan JN**, Jabbes M, Tripp CD, Settles ML. Array-based definition of the CpG island DNA methylation of canine chronic lymphocytic leukemia. 30th Annual Conference Proceedings of the Veterinary Cancer Society, San Diego, CA, 2010.

51) Tripp CD, Fidel J, Anderson CL, Patrick M, Pratt C, Sellon R, **Bryan JN**. A tolerability trial of metronomic lomustine in dogs with cancer. 30th Annual Conference Proceedings of the Veterinary Cancer Society, San Diego, CA, 2010.

50) Fidel J, Lyons J, **Bryan JN**, Tripp C, Sellon R. Radiation therapy for treatment of lower urinary tract tumors: a retrospective of 25 dogs. 2010 Annual Scientific Meeting of the American College of Veterinary Radiology. Aug 15-19, 2010, Ashville NC.

49) Achanta S, Ritchey J, Devine D, **Bryan J**, Broaddus K, Maxwell L. Pharmacokinetic scaling of renal drug clearance. 30th Annual Conference Proceedings of the Veterinary Cancer Society, San Diego, CA, 2010.

48) Clifford CA, Vail D, Thamm D, **Bryan J**, Gill V Carreras J, Fulton L, McNeill C, Klein MK, Ettinger S, Fineman L, Novasad A, Cadile C, Meleo K, Jones P, Gamblin R, London C. Biologic

activity of Palladia in canine anal gland anal sac adenocarcinoma (AGASACA). 30th Annual Conference Proceedings of the Veterinary Cancer Society, San Diego, CA, 2010.

47) **Bryan JN,** Jabbes M, Tripp CD. Immunoprecipitation to Screen Lymphoma Cells for Hypermethylation. ACVIM Forum, Anaheim, CA, June 2010.

46) Ringen KS, Lewis MR, Lattimer JC, Selting KA, **Bryan JN**, Villamil JA, Henry CJ. Comparison of Somatostatin Analogues and Conventional Imaging Modalities for Staging of Canine B-Cell Lymphoma. 29th Annual Conference Proceedings of the Veterinary Cancer Society, Austin, TX, October 16-19, 2009.

45) Tripp CD, Mattoon JS**, Bryan JN,** Sellon RK, Fidel JL. Ultrasound measurement of adrenal size in dogs with atypical Cushing's. 29th Annual Conference Proceedings of the Veterinary Cancer Society, Austin, TX, October 16-19, 2009.

44) **Bryan JN**, Anderson CL, Jabbes M, Fidel J. Pretreatment with valproic acid increases radiation effect on lymphoma cells *in vitro*. 29th Annual Conference Proceedings of the Veterinary Cancer Society, Austin, TX, October 16-19, 2009.

43) CD Tripp, **JN Bryan**, M Jabbes, JL Fidel, RK Sellon, JS Mattoon. The canine orthologues of genes *LHX2* and *POU3F3* are hypermethylated in dogs with lymphoma. Student Research Day, WSU College of Veterinary Medicine, October 14, 2009.

42) J Fidel, R Houston, B Wheeler, C Tripp, **J Bryan**. Accelerated radiation therapy with concomitant carboplatin for treatment of feline oral squamous cell carcinoma—a pilot study. 2008 ACVR Annual Scientific Meeting, San Antonio, TX, October 21-25, 2008.

41) CD Tripp, **JN Bryan**, M Jabbes, JL Fidel, RK Sellon, JS Mattoon. The canine orthologues of genes *LHX2* and *POU3F3* are hypermethylated in dogs with lymphoma. 28th Annual Conference Proceedings of the Veterinary Cancer Society, Seattle, WA, October 18-21, 2008.

40) **Bryan JN**, Rissetto KC, Henry CJ, Fidel JL, McCaw DL, Johnson KD, Sellon RK, Selting KA, Tripp CD, Rankin WV, Villamil JA. Phase I evaluation of a carboplatin and doxorubicin combination chemotherapy protocol for dogs with osteosarcoma. 28th Annual Conference Proceedings of the Veterinary Cancer Society, Seattle, WA, October 18-21, 2008.

39) Statham K, Lewis MR, Green J, Lattimer J, **Bryan JN**, Henry CJ, Selting KA, Besch-Willaford C, Molecular Imaging of the bcl-2 Oncogene in Canine B-Cell Lymphoma. 28th Annual Conference Proceedings of the Veterinary Cancer Society, Seattle, WA, October 18-21, 2008.

38) Wininger FA, Holmes SP, Bagley RS, Chen AV, Hicks DG, **Bryan JN,** Correlation of MR Imaging Meningeal Enhancement or CSF Flair-Suppression with CSF Analysis in Dogs. 26th Annual Forum of the American College of Veterinary Internal Medicine, San Antonio, Texas, June 4-7, 2008

37) Lewis MR, Statham KA, **Bryan JN**, Jia F, Balaji BS, Villamil JA, Selting KA, Henry CJ, Lattimer JC, Molecular imaging of somatostatin receptors and the bcl-2 cellular oncogene in canine B-cell lymphoma. Midwest Regional Meeting of the American Chemical Society, 2008

36) Lewis MR, **Bryan JN**, Jia F, Villamil JA, Selting K, Henry CJ, Somatostatin Receptor Imaging of Canine B-cell Lymphoma. 27th Annual Conference Proceedings of the Veterinary Cancer Society, Fort Lauderdale, FL, November 1-4, 2007

35) Bommarito DA, **Bryan JN**, Cutler CS, Lattimer JC, Ketring AR, Henry CJ, Systemic toxicity of Lu-177-DOTMP administered intravenously to normal dogs. 27th Annual Conference Proceedings of the Veterinary Cancer Society, Fort Lauderdale, FL, November 1-4, 2007

34) **Bryan JN**, Arthur GL, Taylor KH, Rhamatpanah F, Henry CJ, Lewis MR, Caldwell CW, Hypermethylation of DLC1 CpG Island in Canine Lymphoma. 27th Annual Conference Proceedings of the Veterinary Cancer Society, Fort Lauderdale, FL, November 1-4, 2007

33) **JN Bryan**, F Jia, ER Balkin, MR Lewis, The Synergistic Interaction of Radiation and Zebularine is Dependent on Radiation Quality. 27th Annual Conference Proceedings of the Veterinary Cancer Society, Fort Lauderdale, FL, November 1-4, 2007

32) Cutler CS, **Bryan JN**, Chandia M, Irwin DJ, Engelbrecht HP, Rold T, Lattimer J, Hoffman T, Henry C J, Ketring AR. Evaluation of ^{177}Lu Labeled DOTMP and EDTMP. 17th International Symposium on Radiopharmaceutical Sciences to be held in Aachen, Germany April, 2007.

31) **Bryan JN**, Taylor KH, Henry CJ, Selting KA, Lewis MR, McCaw DL, Johnson KD, Rankin WV, Caldwell CW. Comparative epigenetics of a tumor suppressor gene in canine lymphomas. 26th Annual Conference Proceedings of the Veterinary Cancer Society, Calloway Gardens, GA, October 19-22, 2006. p.43.

30) McCaw DL, Alexander H, Alexander S, **Bryan JN**, Turnquist S, Henry CJ, Chan AS, Selting KA, Johnson KD. Identification of proteome differences between normal and cancerous lymph nodes in dogs. 26th Annual Conference Proceedings of the Veterinary Cancer Society, Calloway Gardens, GA, October 19-22, 2006. p.41.

29) Villamil JA, Tyler JW, **Bryan JN**, McCaw DL, Keeler MR, Hahn AW, Henry CJ. Use of the Veterinary Medical Database to update epidemiological data in the veterinary oncology literature. 26th Annual Conference Proceedings of the Veterinary Cancer Society, Calloway Gardens, GA, October 19-22, 2006. p.24. Resident Award Winner

28) **Bryan JN**, Taylor, KH, Henry CJ, Selting KA, Lewis MR, Caldwell CW. *In silico* and *in vivo* identification of a new methylated cancer gene. National Library of Medicine Informatics Training Conference, Nashville, KY, June 27-28, 2006.

27) Rankin WV, Henry CJ, Rucker EB, **Bryan JN,** Tyler JW, Turk JW. Evaluation of survivin in Canine urinary bladder transitional cell carcinomas. Life Sciences Week, University of Missouri-Columbia, April 2006. Resident Award Winner

26) **Bryan JN**, Taylor KH, Henry CJ, Selting KA, Rahmatpanah F, Caldwell CW. *In silico* and *in vivo* identification of a novel methylated canine cancer gene. University of Missouri Life Sciences Week, April 2006.

25) **Bryan JN**, Taylor KH, Rahmatpanah F, and CW Caldwell. Identification of comparative epigenomic targets using web-based informatics tools. University of Missouri-Columbia, Health Sciences Research Day, November 10, 2005.

24) Henry CJ, Lattimer JL, Milner RJ, Tyler JW, McCaw DL, Selting KS, **Bryan JN**, Johnson KD, Higginbotham ML, Kunz DA, Garro M, Harbke LM. Effect of carboplatin administration on bone uptake of Samarium-153-EDTMP in dogs with osteosarcoma. 25th Annual Conference Proceedings of the Veterinary Cancer Society, Huntington Beach, CA, October 20-23, 2005. p.66.

23) **Bryan JN,** Henry CJ, Hahn AW, and Caldwell CW. A population study of neutering status as a risk factor for prostate cancer. 25th Annual Conference Proceedings of the Veterinary Cancer Society, Huntington Beach, CA, October 20-23, 2005. p. 95.

22) Lewis MR, **Bryan JN**, Pardo IDR, Jia F, Kunz DA, Besch-Williford CL, Theodore LJ, and Axworthy DB. Antibody pretargeting for molecular imaging of canine metastatic prostate cancer. 25th Annual Conference Proceedings of the Veterinary Cancer Society, Huntington Beach, CA, October 20-23, 2005. p. 42.

21) Mohsin, H, Sivaguru, G, Jia, F, **Bryan, JN**, Cutler, CS, Ketring, AR, Athey, PS, Simón, J, Frank, RK, Theodore, LJ, Axworthy, DB, Jurisson, SS, and Lewis, MR. Comparison of Pretarget and Conventional CC49 Radioimmunotherapy Using 149Pm, 166Ho and 177Lu. *J. Labelled Cpd. Radiopharm.*, 48: S21, 2005.*

20) Lewis, MR, **Bryan, JN**, Jia, F, Mohsin, H, Sivaguru, G, Miller, WH, Henry, CJ, and Anderson, CJ. Comparison of High Resolution Mouse PET/CT Imaging and Conventional Biodistributions of Copper-64-labelled Antibodies. *J. Labelled Cpd. Radiopharm.*, 48: S62, 2005.*

19) Lewis, MR, Mohsin, H, Sivaguru, G, Jia, F, **Bryan, JN,** Cutler, CS, Ketring, AR, Athey, PS, Simon, J., Frank, RK, Theodore, LJ, Axworthy, DB, and Jurisson, SS. Therapeutic radiolanthanides for antibody pretargeting: comparisons of delivery platforms, dose rates, and radiation energetics. Pacifichem 2005, Honolulu, HI, December 2005.

18) **Bryan JN**, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, Henry CJ, and Lewis MR (Sponsor). Comparison of high resolution mouse PET/CT imaging and conventional biodistributions of copper-64-labeled antibodies. University of Missouri-Columbia Life Sciences Week, 2005.

17) Figueroa SD, Winkelmann CT, **Bryan JN**, Lewis MR, and Hoffman TJ. Towards longitudinal imaging: Micro-PET/CT applications in radiotracer uptake in small animal models. University of Missouri-Columbia Life Sciences Week, 2005.

16) **Bryan JN**, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, Henry CJ, and Lewis MR (Sponsor). Comparison of high resolution mouse PET/CT imaging and conventional biodistributions of copper-64-labeled antibodies. University of Missouri College of Veterinary Medicine Phi Zeta Research Day, April 8, 2005.

15) Tripp CD, **Bryan JN**, Selting KA (Sponsor. The effect of serum T4 and TSH on intensity of thyroid scanning in dogs with thyroid carcinoma. University of Missouri College of Veterinary Medicine Phi Zeta Research Day, April 8, 2005.

14) Lewis MR, **Bryan JN**, Pardo IDR, Jia F, Kunz DA, Besch-Williford CL, Theodore LJ, and Axworthy DB. Imaging of canine metastatic prostate cancer using CC49 pretarget radioimmunoscintigraphy. Proceedings ISRT, 2005.

13) Lewis MR, **Bryan JN**, Pardo IDR, Jia F, Kunz DA, Besch-Williford CL, Theodore LJ, and Axworthy DB. Imaging of canine metastatic prostate cancer using CC49 pretarget radioimmunoscintigraphy. University of Missouri-Columbia Life Sciences Week, 2005.

12) Lewis MR, **Bryan JN**, Jia F, Mohsin H, Sivaguru G, Miller WH, Henry CJ, and Anderson CJ. Comparison of high resolution mouse PET/CT imaging and conventional biodistributions of copper-64-labelled antibodies. *J Labelled Cpd Radiopharm*, submitted.*

11) Mohsin H, Sivaguru G, Jia F, **Bryan JN**, Cutler CS, Ketring AR, Athey PS, Simón J, Frank RK, Theodore LJ, Axworthy DB, Jurisson, SS, and Lewis, MR. Comparison of Pretarget and Conventional CC49 Radioimmunotherapy Using ^{149}Pm, ^{166}Ho and ^{177}Lu. *J Labelled Cpd Radiopharm*, submitted.*

10) **Bryan JN**, Jia F, Mohsin H, Sivaguru G, Siegall CB, Anderson CJ, Henry CJ, Lewis MR. Comparison of internalizing and non-internalizing monoclonal antibodies for copper-64 radioimmunotherapy in mice bearing colon cancer xenografts. 24th Annual Conference Proceedings of the Veterinary Cancer Society, Kansas City, MO, November 3-6, 2004. p. 33.

9) Lewis MR, Mohsin H, Sivaguru G, Jia F, **Bryan JN,** Shelton TD, Hoffman TJ, Cutler CS, Ketring AR, Athey PS, Simón J, Frank RK, Axworthy DB, and Jurisson SS. Radiolanthanides for pretarget and conventional radioimmunotherapy of cancer: "Magic bullets" versus "smart bombs." World Conference on Magic Bullets, Celebrating Paul Ehrlich's 150th Birthday, Nürnberg, Germany, September 2004.

8) **Bryan JN**, Mohsin H, Jia F, Sivaguru G, Siegall CB, Anderson CJ, Miller WH, Henry CJ, and Lewis MR. Biodistributions and tumor dosimetry of copper-64-labeled DOTA-cBR96 and DOTA-cT84.66 in xenograft-bearing mice. *J Nucl Med* 45: 433P, 2004.*

7) Mohsin H, Sivaguru G, Jia F, **Bryan JN**, Shelton TD, Hoffman, TJ, Theodore LJ, Axworthy DB, Simon J, Frank RK, Embree MF, Cutler CS, Ketring AR, Jurisson SS, Lewis MR. Lanthanide radiopharmaceuticals for pretarget and conventional radioimmunotherapy of cancer. University of Missouri-Columbia Life Sciences Week, 2004.

6) **Bryan JN**, Mohsin H, Jia F, Sivaguru G, Sigall CB, Anderson CJ, Miller WH, Henry CJ, Lewis MR. Biodistributions and tumor dosimetry of copper-64-labeled DOTA-cBR96 and DOTA-cT84.66 in xenograft-bearing mice. University of Missouri Life Sciences Week, April 2004.

5) **Bryan JN**, Mohsin H, Jia F, Sivaguru G, Sigall CB, Anderson CJ, Miller WH, Henry CJ, Lewis MR. Biodistributions and tumor dosimetry of copper-64-labeled DOTA-cBR96 and DOTA-cT84.66 in xenograft-bearing mice. University of Missouri College of Veterinary Medicine Phi Zeta Research Day, April 23, 2004.

4) **Bryan JN,** Mohsin H, Jia F, Siegall CB, Anderson CJ, Miller WH, Henry CJ, Lewis MR. A two-antibody model for copper-64 radioimmunotherapy: Biodistributions and tumor dosimetry in a mouse model of cancer. *Veterinary and Comparative Oncology* 2004; 2(2): 99P

3) **Bryan JN**, Lewis MR, Henry CJ, Siegall CB, Anderson CJ. Copper-64 labeled antibodies for the radioimmunotherapy of cancer. Proceedings of the 23rd Annual Conference of the Veterinary Cancer Society, Madison, WI, 2003, p. 6. Resident Award Winner

2) **Bryan JN**. Proteomic evaluation of nodal and circulating lymphocytes of normal dogs. University of Missouri College of Veterinary Medicine Phi Zeta Research Day, April 11, 2003.

1) **Bryan JN**, Jackson T, Henry CJ, Turnquist S, Allen T, Jones R, Simcik C, Slawienski MJ, Steinberg HS. Canine renal neoplasms: A retrospective of 30 cases. Proceedings of the 22nd Annual Conference of the Veterinary Cancer Society, New York, NY, September, 2002, p. 26.
* = peer reviewed

Presentations:

Morning Rounds: Targeting CTLA-4 in Companion Animal Cancer Care, Veterinary Cancer Society Annual Conference, September 25-27, 2024, Salt Lake City, UT

Companion Animal Models for Cancer Epigenomics. Genomics in Medicine Seminar Series. Washington University in St. Louis, February 22, 2023.

Above the Genome: Targeting Strategies for Cancer. Veterinary Cancer Society Midyear Conference. Puerto Vallarta, Mexico, April 10-12, 2022.

Comparative Oncology: Advancing Health at Both Ends of the Leash, Siteman Cancer Center Solid Tumor Therapeutics Program, February 22, 2022.

Epigenomics of Cancer. 2020 Veterinary Cancer Society Annual Conference. Virtual conference, October 16-18, 2020.

Autologous Activated T Cell Therapy for Osteosarcoma of Companion Dogs. Society for the Immunotherapy of Cancer, National Harbor, MD, November 6-9, 2019.

PET Imaging in a Comparative and Translational Oncology Program. National Cancer Institute, Bethesda, MD, May 16, 2019.

Clinical trials in immunotherapy and imaging: seeing our way to future cures. Veterinary Eastern Cooperative Oncology Group, New York City, April 7, 2019.

Oh the places you'll go on three legs. Science Café, University of Missouri, Columbia MO, February 27, 2019.

Naturally-occurring cancers in companion dogs give insights to cancer epigenetics, immunotherapy, and novel therapeutics, Medical Pharmacology and Physiology Lecture Series, University of Missouri, February 5, 2019.

Autologous Activated T Cell Therapy for Osteosarcoma of Companion Dogs, Paws For a Cure Research Symposium. Boston, MA, November 12, 2018

Searching for Markers of B Cell Lymphoma in Golden Retrievers: Methylation Signature that Yields Biomarkers of Disease, 2018 NAIA Conference, Orlando FL, October 27, 2018.

The Epigenetic Fingerprints of Diffuse Large B Cell Lymphoma (DLBCL) in Golden Retrievers, Golden Retriever Club of America national specialty show. St. Louis, MO, October 3, 2018.

Our Companion Animals Help Us See Disease More Clearly, University of Missouri Precision Medicine Summit, June 20, 2018.

Science of Oncology Epigenetics of Cancer, American College of Veterinary Internal Medicine Science of Oncology Course, Spring 2018.

Companion Dogs Help Researchers Collar Cancer, University of Missouri, Saturday Science, May 21, 2018.

Application of Radiopharmaceutical Drugs for PET Imaging and Cancer Therapy in Companion Animals, Oregon State University, February 13, 2018.

DNA Methylation Signature of Diffuse Large B Cell Lymphoma of Golden Retrievers Offers Potential Biomarkers of Diagnosis, Prognosis, and Risk, University of Missouri Cancer Research Group, November 9, 2017

DNA Methylation Signature of Diffuse Large B Cell Lymphoma of Golden Retrievers Offers Potential Biomarkers of Diagnosis, Prognosis, and Risk, ASCVP Symposium at the ACVP Annual Meeting, Vancouver, B. C., November 5, 2017

Translational Context of One Health, Inaugural One Health Conference, St. Louis Zoo, September 30, 2016

Searching for Stem Cell Signatures in Canine DNA Methylation for Health Translation. Grand Rounds, Women's and Children's Hospital, Columbia, MO, November 6, 2015.

The Concept of One Health, One Medicine. Rotary Club District Meeting, Lake of the Ozarks, MO, October 24, 2015.

Are there treatable epigenetic stem cell targets in cancer? University of Florida, October 22, 2015.

When Does PET Not Mean Your Dog? Department of Chemistry DYNAMITE Lecture Series, University of Missouri, October 5, 2015.

Osteosarcoma. Clinical Oncology and Clinical Trial Opportunities in the Greater Kansas City Region, K-State Olathe, October 1, 2015.

Are there treatable epigenetic targets in cancer stem cells? Epigenetics at MU Chalk Talk, University of Missouri, October 1, 2015.

Epigenetics in Cancer, a Comparative View. Ellis Fischel Oncology Fellow Basic Science Lecture, University of Missouri, August 20, 2015.

DNA Methylation in Canine Lymphoma. AKC Canine Health Foundation 2015 National Parent Club Canine Health Conference. St. Louis, MO. August 7-9, 2015.

Canine Cancer. VetVine webinar, May 27, 2015.

Veterinary and Comparative Oncology Applications of Radiopharmaceuticals. University of Florida, May 14, 2015.

Industry Panel on One Health Big Data Applications. University of Missouri Informatics Symposium. April 28, 2015.

Comparative Examination of Cancer: Cross-species Lessons. Boone County Medical Society. March 3, 2015.

Translating Oncology Discoveries through Imaging in Companion Dog Trials. Translational Research Seminar Series, Biological Therapeutics Center, Washington University St. Louis, February 20, 2015.

The Development of a Novel Vaccine Strategy for Aggressive Metastatic Cancer. ICATS Seminar, University of Missouri, January 13, 2015.

The Concept of One Health, One Medicine. Rotary Club, Columbia, MO, April 24, 2014.

The Common Epigenetic Threads of Cancer in Dogs and Humans. Saturday Science, University of Missouri, February 1, 2014.

DNA Methylation in Cancers of Dogs and Humans: Comparative Path to Biologically High-Value Targets. Oncology Grand Rounds. Ellis Fischel Cancer Center, University of Missouri, April 16, 2013.

DNA Methylation in Lymphomas of Dogs and Humans: Comparative Path to Biologically High-Value Targets. Veterinary Eastern Cooperative Oncology Group Annual Meeting. New York City, NY, April 14, 2013.

DNA Methylation in Cancers of Dogs and Humans: Comparative Path to Biologically High-Value Targets. Mari Lowe Center for Comparative Oncology Seminar Series. University of Pennsylvania, 21 March 2013.

Epigenetic Contributions to Lung Disease. 30th Annual Veterinary Comparative Respiratory Society Symposium, University of Missouri, October 2012.

DNA Methylation: Understanding Dogs To Understand Humans. ACVIM Forum One Medicine Lecture. New Orleans, LA, June 2012.

Comparative Oncology Laboratory: Basic Science to Veterinary Oncology Translational Trials and Back. Radiopharmaceutical Sciences Institute, University of Missouri, September 14, 2011.

Epigenetic Derangements of Canine Lymphoma. School of Molecular Biosciences Seminar, Washington State University, September 9, 2010.

Epigenetic Derangements of Canine Lymphoma. Resident Seminar, Washington State University, 2009.

Comparative Oncology: Dogs, People, and Cancer. Keynote Address. 9th Annual Community Oncology Meeting, Whistler, BC, June 20, 2009.

DNA methylation in cancer: techniques and preliminary evidence of hypermethylation in canine lymphoma. Theilen Tribute Symposium. UC Davis, June 2008.

Epigenomic Alterations and Cancer: Cause or Result? VMS 582 Faculty/Resident/Seminar, Washington State University. March 5, 2008.

Epigenomic Alterations and Cancer: Cause or Result? Advanced Oncology graduate course, University of Missouri, January 30, 2008.

Epigenomics: the dog as a comparative oncology model. Pharmacology/Toxicology Seminar Series, Washington State University, January 25, 2008.

***DLC1* as a Comparative Epigenetic Biomarker for Radiotherapy of Non-Hodgkin's Lymphoma.** Dissertation defense, June 13, 2007.

Oncology Decision Making in Exotic Patients. University of Missouri – College of Veterinary Medicine, 5th Annual Exotic Animal Symposium, January 13th - 14th, 2007.

Oncology: the Roles of Complementary Therapies. Washington State University, invited presentation. September 2006.

Identification of Comparative Epigenomic Targets Using Web-Based Informatics Tools. University of Missouri-Columbia Health Sciences Research Day, 2005. (Poster)

A population study of neutering status as a risk factor for prostate cancer. 25th Annual Conference of the Veterinary Cancer Society, Huntington Beach, CA, October 20-23, 2005 (Poster)

Comparison of high resolution mouse PET/CT imaging and conventional biodistributions of copper-64-labeled antibodies. University of Missouri-Columbia Life Sciences Week, 2005. (Poster)

Comparison of high resolution mouse PET/CT imaging and conventional biodistributions of copper-64-labeled antibodies. University of Missouri College of Veterinary Medicine Phi Zeta Research Day, April 8, 2005. (Poster)

Copper-64-labeled antibodies for the radioimmunotherapy of colon cancer in a mouse model. Masters thesis defense, December 3, 2004.

Comparison of internalizing and non-internalizing monoclonal antibodies for copper-64 radioimmunotherapy in mice bearing colon cancer xenografts. University of Missouri College of Veterinary Medicine Resident Seminar, October 2004.

Biodistributions and tumor dosimetry of copper-64-labeled DOTA-cBR96 and DOTA-cT84.66 in xenograft-bearing mice. University of Missouri Life Sciences week, April 2004. (Poster)

Biodistributions and tumor dosimetry of copper-64-labeled DOTA-cBR96 and DOTA-cT84.66 in xenograft-bearing mice. University of Missouri College of Veterinary Medicine Phi Zeta Research Day, April 2004.

Canine leukemias. University of Missouri College of Veterinary Medicine Resident Seminar, February 2004.

Proteomic evaluation of nodal and circulating lymphocytes of normal dogs University of Missouri College of Veterinary Medicine Phi Zeta Research Day, April 2003.

Canine renal neoplasms: A retrospective of 52 cases. University of Missouri College of Veterinary Medicine Resident Seminar, October 2002.